A PROCESS FOR PREPARING AN ANTI-OXIDANT

Abstract: A process of preparing an anti-oxidant is described. The process comprises preparing a medium that comprises an anti-oxidant and at least one other component. The process comprises preparing in situ in the medium the anti-oxidant. The anti-oxidant is prepared from either a glucan by use of recombinant DNA techniques and/or by use of a recombinant glucan lyase.

Description: N PROCESS OF PREPARING AN ANTI-OXIDANT The present invention relates to a process of preparing an anti-oxidant. An anti-oxidant prevents, inhibits or reduces the oxidation rate of an oxidisable medium. In particular, anti-oxidants are used for the preservation of food, especially when the food is or comprises a fat. Typical chemical anti-oxidants include aromatic amines, substituted phenols and sulphur compounds. Examples of anti-oxidants for food products are polyvinylpolypyrrolidone, dithiothreitol, sulphur dioxide, synthetic γ-tocopherol, δ-tocopherol, L-ascorbic acid, sodium L-ascorbate, calcium L- ascorbate, ascorbyl palmitate, propyl gallate, octyl gallate, dodecyl gallate, lecithin, diphenylamine ethoxyquin and butylated hydroxy toluene. Two commonly used antioxidants are GRINDOX 142 (obtained from Danisco A/S) and GRINDOX 1029 (obtained from Danisco A/S). Typically, anti-oxidants are added to foodstuffs, such as beverages. For example, anti-oxidants are used in the preparation of alcoholic beverages such as beer, cider, ale etc.. In particular, there is a wide spread use of anti-oxidants in the preparation of wine. In this regard, Butzke and Bisson in Agro-Food-Industry HiTech (July/ August 1996 pages 26-30) present a review of wine manufacture. According to Butzke and Bisson (ibid): s "Wine is the product of the natural fermentation of grape must or juice. In the case of red wine, the skins are present during the initial fermentation to allow extraction of pigment and important flavour and aroma constituents from the skin. The term "must" refers to the crushed whole grapes. In the case of white wine production, skins are removed prior to fermentation and only the juice is retained and processed Grapes are harvested and brought directly to the winery from the field. The grapes are then crushed at the winery and the must either transferred to a tank for fermentation (red wine) or pressed to separate juice from the skin and seeds (white wine). In this latter case, -the juice is then transferred to a tank for fermentation. The tanks may either be inoculated with a commercial wine strain of Saccharomyces or allowed to undergo a natural or uninoculated fermentation. In a natural fermentation, Saccharomyces cells are greatly outnumbered by wild (non-Saccharomyces) yeast and bacteria at the beginning of fermentation. By the end of the fermentation Saccharomyces is the dominant and most often only organism isolateable. Inoculation with a commercial wine strain or with fermenting juice or must changes the initial ratio of the numbers of different microorganisms, allowing Saccharomyces to dominate the fermentation much earlier. The metabolic activity of microorganisms in wine results in the production of aroma and flavour compounds some of which are highly objectionable to the consumer and all of which are distinct from the compounds responsible for the varietal character of the wine Sulphur dioxide addition prevents chemical oxidation reactions and in this sense is an important stabilizer of the natural grape aroma and flavour. It may be added to the must or juice to preserve flavour, not necessarily as an antimicrobial agent. However, its antimicrobial activity must be considered when choosing a strain to be genetically modified for wine production. " Hence, potentially harmful chemicals - such as sulphur dioxide - are used in wine manufacture. The present invention seeks to overcome any problems associated with the prior art methods of preparing foodstuffs with antioxidants. According to a.first aspect of the present invention there is provided a process of preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; and wherein the anti-oxidant is prepared from a glucan by use of recombinant DNA techniques. According to a second aspect of the present invention there is provided a process of preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; and wherein the anti-oxidant is prepared by use of a recombinant glucan lyase. According to a third aspect of the present invention there is provided a medium prepared by the process according to the present invention. Other aspects of the present invention include: Use of anhydrofructose as an anti-oxidant for a medium comprising at least one other component, wherein the anhydrofructose is prepared in situ in the medium. Use of anhydrofructose as a means for imparting or improving stress tolerance in a plant, wherein the anhydrofructose is prepared in situ in the plant. Use of anhydrofructose as a means for imparting or improving the transformation of a grape, wherein the anhydrofructose is prepared in situ in the grape. Use of anhydrofructose as a means for increasing antioxidant levels in a foodstuff (preferably a fruit or vegetable, more preferably a fresh fruit or a fresh vegetable), wherein the anhydrofructose is prepared in situ in the foodstuff. Use of anhydrofructose as a. pharmaceutical in a foodstuff, wherein the anhydrofructose is prepared in situ in the foodstuff. A method of administering a foodstuff comprising anhydrofructose, wherein the anhydrofructose is in a pharmaceutically acceptable amount and acts as a pharmaceutical; and wherein the anhydrofructose has been prepared in situ in the foodstuff. Use of anhydrofructose as a nutraceutical in a foodstuff, wherein the anhydrofructose is prepared in situ in the foodstuff. A method of administering a foodstuff comprising anhydrofructose, wherein the anhydrofructose is in a nutraceutically acceptable amount and acts as a nutraceutical; and wherein the anhydrofructose has been prepared in situ in the foodstuff. Use of glucan lyase as a means for imparting or improving stress tolerance in a plant, wherein the glucan lyase is prepared in situ in the plant. Use of glucan lyase as a means for imparting or improving the transformation of a grape, wherein the glucan lyase is prepared in situ in the grape. Use of glucan lyase as a means for increasing antioxidant levels in a foodstuff (preferably a fruit or vegetable, more preferably a fresh fruit or a fresh vegetable), wherein the glucan lyase is prepared in situ in the foodstuff. Use of glucan lyase in the preparation of a pharmaceutical in a foodstuff, wherein the glucan lyase is prepared in situ in the foodstuff. A method of administering a foodstuff comprising an antioxidant, wherein the antioxidant is in a pharmaceutically acceptable amount and acts as a pharmaceutical; and wherein the antioxidant has been prepared in situ in the foodstuff from a glucan lyase. Use of glucan lyase in the preparation of a nutraceutical in a foodstuff, wherein the glucan lyase is prepared in situ in the foodstuff. A method of administering a foodstuff comprising an antioxidant, wherein the antioxidant is in a nutraceutically acceptable amount and acts as a nutraceutical; and wherein the antioxidant has been prepared in situ in the foodstuff from a glucan lyase. Use of a nucleotide sequence coding for a glucan lyase as a means for imparting or improving stress tolerance in a plant, wherein the nucleotide sequence is expressed in situ in the plant. Use of a nucleotide sequence coding for a glucan lyase as a means for imparting or improving the transformation of a grape, wherein the nucleotide sequence is expressed in situ in the grape. Use of a nucleotide sequence coding for a glucan lyase as a means for increasing antioxidant levels in a foodstuff (preferably a fruit or vegetable, more preferably a fresh fruit or a fresh vegetable), wherein the nucleotide sequence is expressed in situ in the foodstuff. Use of a nucleotide sequence coding for a glucan lyase as a means for creating a pharmaceutical in a foodstuff, wherein the nucleotide sequence is expressed in situ in the foodstuff. A method of administering a foodstuff comprising an antioxidant, wherein the antioxidant is in a pharmaceutically acceptable amount and acts as a pharmaceutical; and wherein the antioxidant has been prepared in situ in the foodstuff by means of a nucleotide sequence coding for a glucan lyase. Use of a nucleotide sequence coding for a glucan lyase as a means for creating a nutraceutical in a foodstuff, wherein the nucleotide sequence is expressed in situ in the foodstuff. A method of administering a foodstuff comprising an antioxidant, wherein the antioxidant is in a nutraceutically acceptable amount and acts as a nutraceutical; and wherein the antioxidant has been prepared in situ in the foodstuff by means of a nucleotide sequence coding for a glucan lyase. The term "nutraceutical" means a compound that is capable of acting as a nutrient (i.e. it is suitable for, for example, oral administration) as well as being capable of exhibiting a pharmaceutical effect and/or cosmetic effect. In contrast to the usual practice of adding anti-oxidants media, such as foodstuffs, we have now found that particular anti-oxidants can be prepared in situ in the medium. The in situ preparation of anti-oxidants is particularly advantageous in that less, or even no, additional anti-oxidants need be added to the medium, such as a food product. The present invention is also believed to be advantageous as it provides a means of improving stress tolerance of plants. The present invention is also advantageous as it provides a means for viably transforming grape. The present invention is further advantageous in that it enables the levels of antioxidants in foodstuffs to be elevated. This may have beneficial health implications. In this regard, recent reports (e.g. Biotechnology Newswatch April 21 1997 "Potent Antioxidants, as strong as those in fruit, found in coffee" by Marjorie Shaffer) suggest that antioxidants have a pharmaceutical benefit, for example in preventing or suppressing cancer formation. General in situ preparation of antioxidants in plants has been previously reviewed by Badiani et al in Agro-Food-Industry Hi-Tech (March/ April 1996 pages 21-26). It is to be noted, however, that this review does not mention preparing in situ antioxidants from a glucan, let alone by use of a recombinant glucan lyase. Preferably, the glucan comprises α-1,4 links. Preferably, the glucan is starch or a unit of starch. Preferably, the glucan is a substrate for a recombinant enzyme such that contact of the glucan with the recombinant enzyme yields the anti-oxidant. Preferably, the enzyme is a glucan lyase. Preferably, the enzyme is an c_-l,4-glucan lyase. Preferably, the enzyme comprises any one of the sequences shown as SEQ ID Nos 1-6, or a variant, homologue or fragment thereof. Preferably, the enzyme is any one of the sequences shown as SEQ ID Nos 1-6. Preferably, the enzyme is encoded by a nucleotide sequence comprising any one of the sequences shown as SEQ ID Nos 7-12, or a variant, homologue or fragment thereof. Preferably, the enzyme is encoded by a nucleotide sequence having any one of the sequences shown as SEQ ID Nos 7-12. Preferably, the anti-oxidant is anhydrofructose. Preferably, the anti-oxidant is 1 ,5-D-anhydrofructose. Preferably, the-medium is, or is used in the preparation of, a foodstuff. Preferably, the foodstuff is a beverage. Preferably, the beverage is an alcoholic beverage. Preferably, the beverage is a wine. Preferably, the anti-oxidant is prepared in situ in the component and is then released into the medium. Preferably, the component is a plant or a part thereof. Preferably, the component is all or part of a cereal or a fruit. Preferably, the component is all or part of a grape. The medium may be used as or in the preparation of a foodstuff, which includes beverages. In the alternative, the medium may be for use in polymer chemistry. In this regard, the in situ generated anti-oxidants could therefore act as oxygen scavengers during, for example, the synthesis of polymers, such as the synthesis of bio-degradable plastic. In accordance with the present invention, the anti-oxidant (preferably anhydrofructose) is prepared in situ in the medium. In other words, the antioxidant (preferably anhydrofructose) that is prepared in situ in the medium is used as an anti-oxidant in the medium. In one emdodiment, the antioxidant (preferably anhydrofructose) that is prepared in situ in the medium is used as the main anti-oxidant in the medium. The term "in situ in the medium" as used herein includes the anti-oxidant being prepared by action of a recombinant enzyme expressed by the component on a glucan - which glucan is a substrate for the enzyme. The term also includes the anti-oxidant being prepared by action of a recombinant enzyme expressed by the component on a glucan - which glucan is a substrate for the enzyme - within the component and the subsequent generation of the anti-oxidant. The term also includes the recombinant enzyme being expressed by the component and then being released into the medium, which enzyme acts on a glucan - which glucan is a substrate for the enzyme - present in the medium to form the anti-oxidant in the medium. The term also covers the presence or addition of another component to the medium, which component then expresses a recombinant nucleotide sequence which results in exposure of part or all of the medium to an anti-oxidant, which anti-oxidant may be a recombinant enzyme or a recombinant protein expressed and released by the other component, or it may be a product of a glucan - which glucan is a substrate for the enzyme - within the medium that has been exposed to the recombinant enzyme or the recombinant protein. The term "by use of recombinant DNA techniques" as used herein includes the anti- oxidant being any obtained by use of a recombinant enzyme or a recombinant protein, which enzyme or protein acts on the glucan. The term also includes the anti-oxidant being any obtained by use of an enzyme or protein, which enzyme or protein acts on a recombinant glucan. The term "starch" in relation to the present invention includes native starch, degraded starch, modified starch, including its components amylose and amylopectin, and the glucose units thereof. The terms "variant" , "homologue" or "fragment" in relation to the enzyme include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant amino acid sequence has α-glucan lyase activity, preferably having at least the same activity of any one of the enzymes shown as SEQ ID No. 1-6. In particular, the term "homologue" covers homo logy with respect to structure and/or function providing the resultant enzyme has α-glucan lyase activity. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to any one of the sequences shown as SEQ ID No.s 1-6. More preferably there is at least 95 % , more preferably at least 98 % , homology to any one of the sequences shown as SEQ ID No. 1-6. The terms "variant" , "homologue" or "fragment" in relation to the nucleotide sequence coding for the enzyme include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for an enzyme having α-glucan lyase activity, preferably having at least the same activity of any one of the enzymes shown as SEQ ID No. 1-6. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for an enzyme having α-glucan lyase activity. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90 % homology to any one of the sequences shown as SEQ ID No. 7-12. More preferably there is at least 95 %, more preferably at least 98% , homology to any one of the sequences shown as SEQ ID No. 7-12. The above terms are synonymous with allelic variations of the sequences. The present invention also covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention. The term "nucleotide" in relation to the present invention includes cDNA. According to the present invention there is therefore provided a method of preparing s in situ in an oxidisable medium an anti-oxidant. In a preferred embodiment, the antioxidant is anhydrofructose, more preferably 1,5-D-anhydrofructose. 1 ,5-D- anhydrofructose has been chemically synthesised (Lichtenthaler in Tetrahedron Letters Vol 21 pp 1429-1432). 1,5-D-anhydrofructose is further discussed in WO 95/10616, WO 95/10618 and GB-B-2294048. The main advantages of using 1 ,5-D-anhydrofructose as an anti-oxidant are that it is a natural product, it is non-metabolisable, it is easy to manufacture, it is water- soluble, and it is generally non-toxic. According to WO 95/10616, WO 95/10618 and GB-B-2294048, 1 ,5-D-anhydrofructose may be prepared by the enzymatic modification of substrates based on α-1,4- glucan by use of the enzyme c.-l,4-glucan lyase. A typical -l,4-glucan based substrate is starch. Today, starches have found wide uses in industry mainly because they are cheap raw materials. There are many references in the art to starch. For example, starch is discussed by Salisbury and Ross in Plant Physiology (Fourth Edition, 1991, Published by Wadsworth Publishing Company - especially section 11.7). In short, however, starch is one of the principal energy reserves of plants. It is often found in colourless plastids (amyloplasts), in storage tissue and in the stroma of chloroplasts in many plants. Starch is a polysaccharide carbohydrate. It comprises two main components: amylose and/or amylopectin. Both amylose and/or amylopectin consist of straight chains of α(l ,4)-linked glucose units (ie glycosyl residues) but in addition amylopectin includes c.(l ,6) branched glucose units. Some of the glucan lyases discussed in WO 95/10616 and WO 95/10618 that are suitable for producing 1,5-D-anhydrofructose from starch are shown as SEQ I.D. No.s 1-4. Some of the glucan lyases discussed in GB-B-2294048 that are suitable for producing 1,5-D-anhydrofructose from starch are shown as SEQ I.D. No.s 5-6. Some of the nucleotide sequences coding for glucan lyases discussed in WO 95/10616 and WO 95/10618 that are suitable for producing 1,5-D-anhydrofructose from starch are shown as SEQ I.D. No.s 7-10. Some of the nucleotide sequences coding for glucan lyases discussed in GB-B-2294048 that are suitable for producing 1 ,5-D- anhydrofructose from starch are shown as SEQ I.D. No.s 11-12. A further glucan lyase is discussed in WO 94/09122. The recombinant nucleotide sequences coding for the enzyme may be cloned from sources such as a fungus, preferably Morchella costata or Morchella vulgaris, or from a fungally infected algae, preferably Gracilariopsis lemaneiformis, or from algae lone, preferably Gracilariopsis lemaneiformis. In a preferred embodiment, the 1 ,5-D-anhydrofructose is prepared in situ by treating an c.-l ,4-glucan with a recombinant «-l ,4-glucan lyase, such as any one of those presented as SEQ I.D. No.s 1-6. Detailed commentary on how to prepare the enzymes shown as sequences SEQ I.D. No.s 1-6 may be found in the teachings of WO 95/10616, WO 95/10618 and GB-B- 2294048. Likewise, detailed commentary on how to isolate and clone the nucleotide sequences SEQ I.D. No.s 7-12 may be found in the teachings of WO 95/10616, WO 95/10618 and GB-B-2294048. If the glucan contains links other than and in addition to the α-1,4- links the recombinant α-l ,4-glucan lyase can be used in conjunction with a suitable reagent that can break the other links - such as a recombinant hydrolase - preferably a recombinant glucanohydrolase. General teachings of recombinant DNA techniques may be found in Sambrook . , Fritsch, E.F. , Maniatis T. (Editors) Molecular Cloning. A laboratory manual. Second edition. Cold Spring Harbour Laboratory Press. New York 1989. In order to express a nucleotide sequence, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include E. coli and Bacillus subtilis. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook et al (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the gene may need to be suitably modified before transformation - such as by removal of introns. In one embodiment, the host organism can be of the genus Aspergillus, such as Aspergillus niger. A transgenic Aspergillus can be prepared by following the teachings of Rambosek, J. and Leach, J. 1987 (Recombinant DNA in filamentous fungi: Progress and Prospects. CRC Crit. Rev. Biotechnol. 6:357-393), Davis R.W. 1994 (Heterologous gene expression and protein secretion in Aspergillus. In: Martinelli S.D. , Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp 525-560), Ballance, D.J. 1991 (Transformation systems for Filamentous Fungi and an Overview of Fungal Gene structure. In: Leong, S.A. , Berka R.M. (Editors) Molecular Industrial Mycology. Systems and Applications for Filamentous Fungi. Marcel Dekker Inc. New York 1991. pp 1-29) and Turner G. 1994 (Vectors for genetic manipulation. In: Martinelli S.D. , Kinghorn J.R.( Editors) Aspergillus: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666). However, the following commentary provides a summary of those teachings for producing transgenic Aspergillus. For almost a century, filamentous fungi have been widely used in many types of industry for the production of organic compounds and enzymes. For example, traditional Japanese koji and soy fermentations have used Aspergillus sp. Also, in this century Aspergillus niger has been used for production of organic acids particular citric acid and for production of various enzymes for use in industry. There are two major reasons why filamentous fungi have been so widely used in industry. First filamentous fungi can produce high amounts of extracelluar products, for example enzymes and organic compounds such as antibiotics or organic acids. Second filamentous fungi can grow on low cost substrates such as grains, bran, beet pulp etc. The same reasons have made filamentous fungi attractive organisms as hosts for heterologous expression of recombinant enzymes according to the present invention. In order to prepare the transgenic Aspergillus, expression constructs are prepared by inserting a requisite nucleotide sequence into a construct designed for expression in filamentous fungi. Several types of constructs used for heterologous expression have been developed. These constructs can contain a promoter which is active in fungi. Examples of promoters include a fungal promoter for a highly expressed extracelluar enzyme, such as the glucoamylase promoter or the α-amylase promoter. The nucleotide sequence can be fused to a signal sequence which directs the protein encoded by the nucleotide sequence to be secreted. Usually a signal sequence of fungal origin is used. A terminator active in fungi ends the expression system. Another type of expression system has been developed in fungi where the nucleotide sequence can be fused to a smaller or a larger part of a fungal gene encoding a stable protein. This can stabilize the protein encoded by the nucleotide sequence. In such a system a cleavage site, recognized by a specific protease, can be introduced between the fungal protein and the protein encoded by the nucleotide sequence, so the produced fusion protein can be cleaved at this position by the specific protease thus liberating the protein encoded by the nucleotide sequence. By way of example, one can introduce a site which is recognized by a KEX-2 like peptidase found in at least some Aspergilli. Such a fusion leads to cleavage in vivo resulting in protection of the expressed product and not a larger fusion protein. Heterologous expression in Aspergillus has been reported for several genes coding for bacterial, fungal, vertebrate and plant proteins. The proteins can be deposited intracellularly if the nucleotide sequence is not fused to a signal sequence. Such proteins will accumulate in the cytoplasm and will usually not be glycosylated which can be an advantage for some bacterial proteins. If the nucleotide sequence is equipped with a signal sequence the protein will accumulate extracelluarly. With regard to product stability and host strain modifications, some heterologous proteins are not very stable when they are secreted into the culture fluid of fungi. Most fungi produce several extracelluar proteases which degrade heterologous proteins. To avoid this problem special fungal strains with reduced protease production have been used as host for heterologous production. For the transformation of filamentous fungi, several transformation protocols have been developed for many filamentous fungi (Ballance 1991 , ibid). Many of them are based on preparation of protoplasts and introduction of DNA into the protoplasts using PEG and Ca 2+ ions. The transformed protoplasts then regenerate and the transformed fungi are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as argB, trpC, niaD and pyrG, antibiotic resistance markers such as benomyl resistance, hygromycin resistance and phleomycin resistance. A commonly used transformation marker is the amdS gene of A. nidulans which in high copy number allows the fungus to grow with acrylamide as the sole nitrogen source. In another embodiment the transgenic organism can be a yeast. In this regard, yeast have also been widely used as a vehicle for heterologous gene expression. The species Saccharomyces cerevisiae has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in Saccharomyces cerevisiae has been reviewed by Goodey et al (1987, Yeast Biotechnology, D R Berry et al, eds, pp 401-429, Allen and Unwin, London) and by King et al (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow). For several reasons Saccharomyces cerevisiae is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of Saccharomyces cerevisiae. A review of -the principles of heterologous gene expression in Saccharomyces cerevisiae and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes" , Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.). Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously replicating plasmid vectors. In order to prepare the transgenic Saccharomyces, expression constructs are prepared by inserting the nucleotide sequence into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed. The constructs contain a promoter active in yeast fused to the nucleotide sequence, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal pep tide, is used. A terminator active in yeast ends the expression system. For the transformation of yeast several transformation protocols have been developed. For example, a transgenic Saccharomyces can be prepared by following the teachings of Hinnen et al (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H et al (1983, J Bacteriology 153, 163-168). The transformed yeast cells are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1 , and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, eg G418. Another host organism is a plant. In this regard, the art is replete with references for preparing transgenic plants. Two documents that provide some background commentary on the types of techniques that may be employed to prepare transgenic plants are EP-B-0470145 and CA-A-2006454 - some of which commentary is presented below. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material. Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205- 225) and Christou (Agro-Food-Industry Hi-Tech March/ April 1994 17-27). Thus, in one aspect, the present invention relates to a vector system which carries a recombinant nucleotide sequence and which is capable of introducing the nucleotide sequence into the genome of an organism, such as a plant, and wherein the nucleotide sequence is capable of preparing in situ an anti-oxidant. The vector system may comprise one vector, but it can comprise at least two vectors. In the case of two vectors, the vector system is normally referred to as a binary vector system. Binary vector systems are described in further detail in Gynheung An et al. (1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19. One extensively employed system for transformation of plant cells with a given promoter or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes (An et al. (1986), Plant Physiol. 81 , 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds. : D.S. Ingrams and J.P. Helgeson, 203-208). Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above. The nucleotide sequence of the present invention should preferably be inserted into the Ti-plasmid between the border -sequences of the T-DNA or adjacent a T-DNA sequence so as to avoid disruption of the sequences immediately surrounding the T- DNA borders, as at least one of these regions appear to be essential for insertion of modified T-DNA into the plant genome. As will be understood from the above explanation, if the organism is a plant, then the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant (e.g. the vir region) and at least one border part of a T- DNA sequence, the border part being located on the same vector as the genetic construct. Preferably, the vector system is an Agrobacterium tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof. In the construction of a transgenic plant the nucleotide sequence or construct or vector of the present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful microorganism is E. coli. , but other microorganisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in E. coli. it is transferred, if necessary, into a suitable Agrobacterium strain, e.g. Agrobacterium tumefaciens. The Ti-plasmid harbouring the first nucleotide sequence or construct of the invention is thus preferably transferred into a suitable Agrobacterium strain, e.g. A. tumefaciens, so as to obtain an Agrobacterium cell harbouring the promoter, or nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified. As reported in CA-A-2006454, a large number of cloning vectors are available which contain a replication system in E. coli and a marker which allows a selection of the transformed cells. The vectors contain for example pBR322, the pUC series, the M13 mp series, pACYC 184 etc. In this way, the promoter or nucleotide or construct of the present invention can be introduced into a suitable restriction position in the vector. -The contained plasmid is used for the transformation in E. coli. The E. coli cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered and then analysed - such as by any one or more of the following techniques: sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA sequence can be restricted or selectively amplified by PCR techniques and connected with the next DNA sequence. Each sequence can be cloned in the same or different plasmid. After each introduction method of the nucleotide sequence or construct or vector according to the present invention in the plants the presence and/or insertion of further DNA sequences may be necessary. If, for example, for the transformation the Ti- or Ri-plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transformation of plant cells has been intensively studied and is described in EP-A- 120516; Hoekema, in: The Binary Plant Vector System Offset-drukkerij Kanters B.B. , Alblasserdam, 1985, Chapter V; Fraley, et al. , Crit. Rev. Plant Sci. , 4: 1-46; and An et al. , EMBO J. (1985) 4:277-284. Direct infection of plant tissues by Agrobacterium is a simple technique which has been widely employed and which is described in Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Patholo gists, eds. : D.S. Ingrams and J.P. Helgeson, 203- 208. For further teachings on this topic see Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/ April 1994 17-27). With this technique, infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant. Typically, with direct infection of plant tissues by Agrobacterium carrying the first nucleotide sequence or the construct, a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound is then inoculated with the Agrobacterium. The inoculated plant or plant part is then grown on a suitable culture medium. When plant cells are constructed, these cells are grown and, optionally,- maintained in a medium according to the present invention following well-known tissue culturing methods - such as by culmring the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc, but wherein the culture medium comprises a component according to the present invention. Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting the transformed shoots and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc. Further teachings on plant transformation may be found in EP-A-0449375. Reference may even be made to Spngstad et al (1995 Plant Cell Tissue Organ Culture 40 pp 1-15) as these authors present a general overview on transgenic plant construction. In one embodiment, the plant is a grapevine. There are a number of teachings in the art on how to prepare transformed grapevines. For example, reference may be made to Baribault et al (J Exp Bot 41 (229) 1990 1045-1050), Baribault et al (Plant Cell Rep 8 (3) 1989 137-140), Scorza et al (J Am Soc Horticultural Science 121 (4) 1996 616-619), Kikkert et al (Plant Cell Reports 15 (5) 1996 311-316), Golles et al (Acta Hortic 1997 vol 447 Number: Horticultural Biotechnology in Vitro Culture and Breeding Pages 265-275), Gray and Scorza (WO-A-97/49277) and Simon Robinson et al (Conference abstracts and paper presented in Biotechnology - Food and Health for the 21st Century, Adelaide, Australia, 1998). By way of example Robinson et al (ibid) disclose a method for transforming grapevine wherein somatic embryos are induced on callus formed from another tissue and Agrobacterium infection is used to transfer target genes into the embryo tissue. Further reference may be made to the teachings of Andrew Walker in Nature Biotechnology (Vol 14, May 1996, page 582) who states that: "The grape, one of the most important fruit plants in the world, has been difficult to engineer because of its high levels of tannins and phenols, which interfere with cell culture and transformation; the compounds oxidize quickly and promote the decay of grape cells. " In that same edition of Nature Biotechnology, Perl et al (pages 624-628) report on the use of the combination of polyvinylpolypyrrolidone and dithiothreitol to improve the viability of grape transformation during Agrobacterium infection. Hence, the present invention provides an alternative means for transforming grape. In this regard, the antioxidant that is prepared in situ by a grape transformed in accordance with the present invention improves the viability of grape transformation during Agrobacterium infection. Thus, according to one aspect of the present invention, there is provided the use of an antioxidant prepared in situ in order to effectively transform a grape. In some instances, it is desirable for the recombinant enzyme or protein to be easily secreted into the medium to act as or to generate an anti-oxidant therein. In such cases, the DNA encoding the recombinant enzyme is fused to inter alia an appropriate signal sequence, an appropriate promoter and v an appropriate terminator from the chosen host. For example, for expression in Aspergillus niger the gpdA (from the Glyceraldehyde- 3 -phosphate dehydrogenase gene of Aspergillus nidulans) promoter and signal sequence is fused to the 5' end of the DNA encoding the mature lyase. The terminator sequence from the A. niger trpC gene is placed 3' to the gene (Punt, P.J. et al 1991 - (1991): J. Biotech. 17, 19-34). This construction is inserted into a vector containing a replication origin and selection origin for E. coli and a selection marker for A. niger. -Examples of selection markers for A. niger are the amdS gene, the argB gene, the pyrG gene, the hygB gene, the BmlR gene which all have been used for selection of transformants. This plasmid can be transformed into A. niger and the mature lyase can be recovered from the culture medium of the transformants. Eventually the construction could be transformed into a protease deficient strain to reduce the proteolytic degradation of the lyase in the medium (Archer D.B. et al 1992 -Biotechnol. Lett. 14, 357-362). In addition, and as indicated above, aside from using Aspergillus niger as the host, there are other industrial important microorganisms which could be used as expression systems. Examples of these other hosts include: Aspergillus oryzae, Aspergillus sp., Trichoderma sp. , Saccharomyces cerevisiae, Kluyveromyces sp. , Hansenula sp., Pichia sp. , Bacillus subtilis, B. amyloliquefaciens, Bacillus sp. , Streptomyces sp. or E. coli. In accordance with the present invention, a suitable marker or selection means may be introduced into the host that is to be transformed with the nucleotide sequence. Examples of suitable markers or selection means are described in any one of WO-A- 93/05163, WO-A-94/20627, GB patent application No. 9702591.0 (filed 7 February 1997), GB patent application No. 9702576.1 (filed 7 February 1997), GB patent application No. 9702539.9 (filed 7 February 1997), GB patent application No. 9702510.0 (filed 7 February 1997) and GB patent application No. 9702592.8 (filed 7 February 1997). s In summation, the present invention relates to a process comprising preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; and wherein the antioxidant is prepared from a glucan by use of recombinant DNA techniques and/or the anti-oxidant is prepared by use of a recombinant glucan lyase. In a preferred- embodiment, the present invention relates to a process a process of preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; and wherein the anti-oxidant is prepared from a glucan by use of a recombinant glucan lyase. In a more preferred embodiment, the present invention relates to a process of preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; wherein the anti-oxidant is prepared from a glucan by use of a recombinant glucan lyase; and wherein the anti-oxidant is anhydro-fructose. The present invention will now be described only by way of example. TRANSGENIC GRAPE Transformed grapes are prepared following the teachings of Perl et al (ibid) but wherein the use of the combination of polyvinylpolypyrrolidone and dithiothreitol is optional. In these studies, the grapes are transformed with any one of the nucleotide sequences presented as SEQ ID No. 7-12. The transformation leads to in situ preparation of 1 ,5-D-anhydrofructose. The transformed grapes are beneficial for one or more of the reasons mentioned earlier. Details on these studies are as follows. Tissue-culture systems for transformation studies The long term somatic embryogenic callus culture is developed from the vegetative tissues of anthers of Vitis vinifera CV Superior Seedless. Methods for another culture, induction of somatic embryogenesis and maintenance of embryogenic cultures, are previously described (Perl et al, 1995, Plant Sci 104: 193-200). Briefly, embryogenic calli are maintained on solidified (0.25 % gelrite) MS medium (Murashige and Skoog, 1962, Physiol Plant 15: 473-497) supplemented with 6% sucrose, 2 mg/L 2,4-diclorophenoxyacetic acid (2,4-D), 5 mg/L Indole-3-aspartic acid (IASP), 0.2 mg/L 6-benzyladenine (BAP) and 1 mg/L abscisic acid (ABA). Proembryogenic calli are induced by transferring the calli to MS medium supplemented with the same phytohormones, but 2,4-D is substituted with 2 mg/L 2- naphthoxy acetic acid (NOA). This stage is used for transformation experiments. Agrobacterium strains For studying the sensitivity of grape embryogenic calli to the presence of different Agrobacterium strains, or for stable transformation experiments, cocultivation is attempted using the following A tumefaciens strains: EHA 101-p492 (Perl et al. 1993, Bio/Technology 11:715-718); LBA 4404-pGPTV (Becker et al, 1992. Plant Mol Biol 20: 1195-1197); and GVE 3101-pPCV91 (Vancanneyt et al, 1990, Mol Gen Genet 220: 245-250). These strains contain the binary vectors conferring resistance to kanamycin (nptIL), basta (bar) and hygromycin (hpt), respectively, all under the control of the nopalin-synthase (NOS) promoter and terminator. Bacteria are cultured with the proper antibiotics in liquid LB medium for 24 hours at 28 °C at 200 rpm. Cocultivation For studying the sensitivity of grape embryogenic calli to different Agrobacterium strains, bacterial cultures with different optical densities (0.1-0.7 at 630 nm) are prepared from an overnight culture of Agrobacterium strains. Bacteria are centrifuged 5 minutes, 5000 rpm and resuspended in antibiotic free McCown's Woody Plant Medium (WPM) (Lloyd and McCown, 1981, Int Plant Prop Soc Proc 30: 421-427). Three grams fresh weight of embryogenic calli (7 days after transfer to NOA containing medium) are resuspended in 10 ml of overnight cultured bacterial suspensions for 5 minutes, dry blotted and transferred to Petri dishes containing regeneration medium [basal WPM medium supplemented with thidiazuron (TDZ) (0.5 mg/L), Zeatin riboside (ZR) (0.5 mg/L), and sucrose (3 %)] . The regeneration medium is solidified with gelrite (0.25 % w/v) and the calli, after initial drainage of excess bacteria, are cocultivated in the dark at 25 °C for different times (5 minutes up to 7 days). .For stable transformation experiments, inoculum (OD 0.6 at 630 nm) is prepared from an overnight culture of LBA 4404 or GVE 3101. Bacteria are centrifuged 5 minutes, 5000 rpm and resuspended in antibiotic-free WPM medium. Embryogenic calli (3g fresh weight) are resuspended in 10 ml of bacteria for 5 minutes, dry blotted and transferred to Petri dishes containing solidified (0.25 % w/v) gelrite regeneration medium supplemented with different antioxidants. The calli are cocultivated for 48 hours in the dark at 25 °C. Selective culture Following 48 hours of cocultivation, the embryogenic callus is maintained in the dark for 7 days on antioxidant containing regeneration medium. Subsequently, the calli are collected on a sterile metal screen and transferred to fresh WPM regeneration medium at 25 °C under 40 μE/m 2 /s (white fluorescent tubes). All regeneration media are supplemented with 400 mg/L claforan, 1.5 g/L malt extract and different selectable markers: kanamycin (50-500 mg/L), hygromycin (15 mg/L) and Basta (1- 10 mg/L). Periodic increases in hygromycin concentration are used. The putative transformed calli are cultured on regeneration medium supplemented with 15 mg/L hygromycin. Every two weeks the regenerating calli are transferred to fresh medium supplemented with 20 and 25 mg/L hygromycin respectively. Control, untransformed grape calli are also cultured on selective media and are periodically exposed to increasing hygromycin concentrations. Green adventitious embryos, which developed on calli cultured for 8-10 weeks on selective regeneration medium, are transferred to germination medium. Embryo germination, rooting and subsequent plantlet development are induced on WPM as described (Perl et al, 1995, Plant Sci 104: 193- 200), supplemented with 25 mg/L hygromycin or 10 mg/L basta. Conversion of vitrified abnormal plantlets into normal-looking grape plantlets are obtained using solidified WPM medium supplemented with 0.1 mg/L NAA as described (Perl et al, 1995, Plant Sci 104: 193-200). TRANSGENIC POTATOES General teachings on potato transformation may be found in our copending patent applications PCT/EP96/03053, PCT/EP96/03052 and PCT/EP94/01082 (the contents of each of which are incorporated herein by reference). For the present studies, the following protocol is adopted. Plasmid construction The disarmed Agrobacterium tumefaciens strain LB A 4404, containing the helper vir plasmid pRAL4404 (Hoekema et al, 1983 Nature 303 pp 179-180), is cultured on YMB agar (K 2 HPO 4 .3H 2 O 660 mg A MgSO 4 200 mg l 1 , NaCl 100 mg l 1 , mannitol 10 g l "1 , yeast extract 400 mg l "1 , 0.8% w/v agar, pH 7.0) containing 100 mg l "1 rifampicin and 500 mg l "1 streptomycin sulphate. Transformation with pVICTOR IV GNG E35S nagB IV2' or pVICTOR IV GNG rbc nagB IV2' or pVICTOR IV GNG E35S nagB' (which correspond to each of pVICTOR IV GNG E35S nagB IV2 or pVICTOR IV GNG rbc nagB IV2 or pVICTOR IV GNG E35S nagB but wherein each of those plasmids also contains any one of the nucleotide sequences shown as SEQ ID No.s. 7-12 operatively linked to a functional promoter) is accomplished using the freeze-thaw method of Holters et al (1978 Mol Gen Genet 163 181-187) and transformants are selected on YMB agar containing 100 mg l "1 rifampicin and 500 mg l "1 streptomycin, and 50 mg l "1 gentamycin sulphate. Transformation of plants Shoot cultures of Solanum tuberosum cv Saturna are maintained on LS agar containing Murashige Skoog basal salts (Sigma M6899) (Murashige and Skoog, 1965, Physiol Plant 15 473-497) with 2 μM silver thiosulphate, and nutrients and vitamins as described by Linsmaier and Skoog (1965 Physiol Plant 18 100-127). Cultures are maintained at 25 °C with a 16h daily photoperiod. After approximately 40 days, subculturing is performed during which leaves are removed, and the shoots cut into mononodal segments of approximately 8 mm length. Shoot cultures of approximately 40 days maturity (5-6 cm height) are cut into 8 mm internodal segments which are placed into liquid LS-medium containing Agrobacterium tumefaciens transformed with pVICTOR IV GNG E35S nagB IV2' or pVICTOR IV GNG rbc nagB IV2' or pVICTOR IV GNG E35S nagB' (A 660 = 0.5, pathlength 1 cm). Following incubation at room temperature for 30 minutes, the segments are dried by blotting on to sterile filter paper and transferred to LS agar (0.8% w/v containing 2 mg l "1 2,4-D and 500 μg l "1 trans-zeatin. The explants are covered with filter paper, moistened with LS medium, and covered with a cloth for three days at 25 °C. Following this treatment, the segments are washed with liquid LS medium containing 800 mg l "1 carbenicillin, and transferred on to LS agar (0.8% w/v) containing 1 mg I "1 trans-zeatin, 100 μg l "1 gibberellic acid (GA3), with sucrose (eg 7.5 g l "1 ) and glucosamine (eg 2.5 g l "1 ) as the selection agent. The segments are sub-cultured to fresh substrate each 3-4 weeks. In 3 to 4 weeks, shoots develop from the segments and the formation of new shoots continues for 3-4 months. Rooting of regenerated shoots The regenerated shoots are transferred to rooting substrate composed of LS-substrate, agar (8 g/1) and carbenicillin (800 mg/1). The transgenic plants may be verified by performing a GUS assay on the co- introduced Aglucuronidase gene according to Hodal, L. et al. (PL Sci. (1992), 87: 115-122). Alternatively, the transgenic genotype of the regenerated shoot may be verified by performing NPTII assays (Radke, S. E. et al, Theor. Appl. Genet. (1988), 75: 685- 694) or by performing PCR analysis according to Wang et al (1993, NAR 21 pp 4153-4154). Transfer to sou The newly rooted plants (height approx. 2-3 cms) are transplanted from rooting substrate to soil and placed in a growth chamber (21°C, 16 hour light 200- 400uE/m 2 /sec). When the plants are well established they are transferred to the greenhouse, where they are grown until tubers had developed and the upper part of the plants are senescing. Harvesting The potatoes are harvested after about 3 months. TRANSGENIC MAIZE PLANTS Introduction Since the first publication of production of transgenic plants in 1983 (Leemans, 1993 Biotechnology 11 s22), there have been numerous publications of production of transgenic plants including especially dicotyledon crop plants. Until very recently there are very few reports on successful production of transgenic monocotyledononary crop plants. This relatively slow development within monocots are due to two causes. Firstly, until the early 1980s, efficient regeneration of plants from cultured cells and tissues of monocots had proven very difficult. This problem is ultimately solved by the culture of explants from immature and embryogenic tissue, which retain their morphogenic potential on nutrient media containing plant growth regulators. Secondly, the monocots are not a natural host for Agrobacterium tumefaciens, meaning that the successful developed techniques within the dicots using their natural vector Agrobacterium tumefaciens is unsuccessful for many years in the monocots. Nevertheless, it is now possible to successfully transformation and produce fertile transgenic plants of maize using methods such as: (1) Silicon Carbide Whiskers; (2) Particle Bombardment; (3) DNA Uptake by PEG treated protoplast; or (4) DNA Uptake in Electroporation of Tissue. Each of these methods - which are reviewed by Thompson (1995 Euphtytica 85 pp 75-80) - may be used to prepare inter alia transgenic maize according to the present invention. In particular, the particle Gun method has been successfully used for the transformation of monocots. However, EP-A-0604662 reports on a different method of transforming monocotyledons. The method comprises transforming cultured tissues of a monocotyledon under or after dedifferentiation with Agrobacterium containing a super binary vector as a selectable marker a hygromycin-resistant gene is used. Production of transgenic calli and plant is demonstrated using the hygromycin selection. This method may be used to prepare inter alia transgenic maize according to the present invention. Subsequent to the method of EP-A-0604662, EP-A-0672752 reports on non- dedifferentiated immature embryos. In this regard, both hygromycin-resistance and PPT-resistance genes are used as the selectable marker, with PPT giving rise to 10% or more independent transformed plants. This method may be used to prepare inter alia transgenic maize according to the present invention. To date, it would appear that transgenic maize plants can be successfully produced from easily-culturable varieties - such as the inbred line A188. In this regard, see the teachings of Ishida et al (1996 Nature Biotechnology 14 pp 745-750). The method disclosed by these workers may be used to prepare inter alia transgenic maize according to the present invention. Vasil (1996 Nature Biotechnology 14 pp 702-703) presents a further review article on transformation of maize. Even though it is possible to prepare transformed maize by use of, for example, particle Gun mediated transformation, for the present studies the following protocol is adopted. Plasmid construction The disarmed Agrobacterium tumefaciens strain LB A 4404, containing the helper vir plasmid pRAL4404 (Hoekema et al, 1983 Nature 303 pp 179-180), is cultured on YMB agar (K 2 HPO 4 .3H 2 O 660 mg l "1 , MgSO 4 200 mg l 1 , NaCl 100 mg 7, mannitol 10 g l "1 , yeast extract 400 mg l "1 , 0.8% w/v agar, pH 7.0) containing 100 mg l "1 rifampicin and 500 mg l "1 streptomycin sulphate. Transformation with pVICTOR IV GNG E35S nagB IV2' or pVICTOR IV GNG rbc nagB IV2' or pVICTOR IV GNG E35S nagB' is accomplished using the freeze-thaw method of Holters et al (1978 Mol Gen Genet 163 181-187) and transformants are selected on YMB agar containing 100 mg l "1 rifampicin and 500 mg l "1 streptomycin, and 50 mg l "1 gentamycin sulphate. Isolation and cocultivation of explants Immature embryos of, for example, maize line A188 of the size between 1.5 to 2.5 mm are isolated and cocultivated with Agrobacterium tumefaciens strain LBA 4404 in N6-AS for 2-3 days at 25 °C under illumination. Thereafter, the embryos are washed with sterilized water containing 250 mg/1 of cefotaxime and transferred to an LS medium and 250 mg/1 cefotaxime and glucosamine in concentrations of up to 100 mg/1 (the medium is hereafter called LSS1). Conditions for the selection of transgenic plants The explants are cultured for three weeks on LSS1 medium and then transferred to an LS medium containing glucosamine and cefotaxime. After three weeks on this medium, green shoots are isolated. Rooting of transformed shoots Transformed shoots are transferred to an MS medium containing 2 mg/1 for rooting. After four weeks on this medium, plantlets are transferred to pots with sterile soil for acclimatisation. TRANSGENIC GUAR PLANTS Transformation of guar cotyledonary explants is performed according to Joersbo and Okkels (PCT/DK95/00221) using Agrobacterium tumefaciens LBA4404 harbouring a suitable plasmid. Other plants may be transformed in accordance with the present invention, such as other fruits, other vegetables, and other plants such as coffee plants, tea plants etc. Other modifications of the present invention will be apparent to those skilled in the art. SEQUENCES ( 1 ) GENERAL INFORMATION ( i ) APPLICANT (A) NAME DANISCO A/S (B) STREET LANGEBROGADE 1 (C) CITY COPENHAGEN (D) STATE COPENHAGEN K (E) COUNTRY DENMARK (F) POSTAL CODE (ZIP) DK-1001 (2) INFORMATION FOR SEQ ID NO 1 (i) SEQUENCE CHARACTERISTICS (A) LENGTH 1088 ami no acids (B) TYPE amino acid (D) TOPOLOGY linear (n) MOLECULE TYPE protein (xi) SEQUENCE DESCRIPTION SEQ ID NO 1 Met Phe Ser Thr Leu Ala Phe Val Ala Pro Ser Ala Leu Gly Ala Ser 1 5 10 15 Thr Phe Val Gly Ala Glu Val Arg Ser Asn Val Arg He His Ser Ala 20 25 30 Phe Pro Ala Val His Thr Ala Thr Arg Lys Thr Asn Arg Leu Asn Val 35 40 45 Ser Met Thr Ala Leu Ser Asp Lys Gin Thr Ala Thr Ala Gly Ser Thr 50 55 60 Asp Asn Pro Asp Gly He Asp Tyr Lys Thr Tyr Asp Tyr Val Gly Val 65 70 75 80 Trp Gly Phe Ser Pro Leu Ser Asn Thr Asn Trp Phe Ala Ala Gly Ser 85 90 95 Ser Thr Pro Gly Gly He Thr Asp Trp Thr Ala Thr Met Asn Val Asn 100 105 110 Phe Asp Arg He Asp Asn Pro Ser He Thr Val Gin His Pro Val Gin 115 120 125 Val Gin Val Thr Ser Tyr Asn Asn Asn Ser Tyr Arg Val Arg Phe Asn 130 135 140 Pro Asp Gly Pro He Arg Asp Val Thr Arg Gly Pro He Leu Lys Gin 145 150 155 160 Gin Leu Asp Trp He Arg Thr Gin Glu Leu Ser Glu Gly Cys Asp Pro 165 170 175 Gly Met Thr Phe Thr Ser Glu Gly Phe Leu Thr Phe Glu Thr Lys Asp 180 185 190 Leu Ser Val He He Tyr Gly Asn Phe Lys Thr Arg Val Thr Arg Lys 195 200 205 Ser Asp Gly Lys Val He Met Glu Asn Asp Glu Val Gly Thr Ala Ser 210 215 220 Ser Gly Asn Lys Cys Arg Gly Leu Met Phe Val Asp Arg Leu Tyr Gly 225 230 235 240 Asn Ala He Ala Ser Val Asn Lys Asn Phe Arg Asn Asp Ala Val Lys 245 250 255 Gin Glu Gly Phe Tyr Gly Ala Gly Glu Val Asn Cys Lys Tyr Gin Asp 260 265 270 Thr Tyr He Leu Glu Arg Thr Gly He Ala Met Thr Asn Tyr Asn Tyr 275 280 285 Asp Asn Leu Asn Tyr Asn Gin Trp Asp Leu Arg Pro Pro His His Asp 290 295 300 Gly Ala Leu Asn Pro Asp Tyr Tyr He Pro Met Tyr Tyr Ala Ala Pro 305 310 315 320 Trp Leu He Val Asn Gly Cys Ala Gly Thr Ser Glu Gin Tyr Ser Tyr 325 330 335 Gly Trp Phe Met Asp Asn Val Ser Gin Ser Tyr Met Asn Thr Gly Asp 340 345 350 Thr Thr Trp Asn Ser Gly Gin Glu Asp Leu Ala Tyr Met Gly Ala Gin 355 360 365 Tyr Gly Pro Phe Asp Gin His Phe Val Tyr Gly Ala Gly Gly Gly Met 370 375 380 Glu Cys Val Val Thr Ala Phe Ser Leu Leu Gin Gly Lys Glu Phe Glu 385 390 395 400 Asn Gin Val Leu Asn Lys Arg Ser Val Met Pro Pro Lys Tyr Val Phe 405 410 415 Gly Phe Phe Gin Gly Val Phe Gly Thr Ser Ser Leu Leu Arg Ala His 420 425 430 Met Pro Ala Gly Glu Asn Asn He Ser Val Glu Glu He Val Glu Gly 435 440 445 Tyr Gin Asn Asn Asn Phe Pro Phe Glu Gly Leu Ala Val Asp Val Asp 450 455 460 Met Gin Asp Asn Leu Arg Val Phe Thr Thr Lys Gly Glu Phe Trp Thr 465 470 475 480 Ala Asn Arg Val Gly Thr Gly Gly Asp Pro Asn Asn Arg Ser Val Phe 485 490 495 Glu Trp Ala His Asp Lys Gly Leu Val Cys Gin Thr Asn He Thr Cys 500 505 510 Phe Leu Arg Asn Asp Asn Glu Gly Gin Asp Tyr Glu Val Asn Gin Thr 515 520 525 Leu Arg Glu Arg Gin Leu Tyr Thr Lys Asn Asp Ser Leu Thr Gly Thr 530 535 540 Asp Phe Gly Met Thr Asp Asp Gly Pro Ser Asp Ala Tyr He Gly His 545 550 555 560 Leu Asp Tyr Gly Gly Gly Val Glu Cys Asp Ala Leu Phe Pro Asp Trp 565 570 575 Gly Arg Pro Asp Val Ala Glu Trp Trp Gly Asn Asn Tyr Lys Lys Leu 580 585 590 Phe Ser He Gly Leu Asp Phe Val Trp Gin Asp Met Thr Val Pro Ala 595 600 605 Met Met Pro His Lys He Gly Asp Asp He Asn Val Lys Pro Asp Gly 610 615 620 Asn Trp Pro Asn Ala Asp Asp Pro Ser Asn Gly Gin Tyr Asn Trp Lys 625 630 635 640 Thr Tyr His Pro Gin Val Leu Val Thr Asp Met Arg Tyr Glu Asn His 645 650 655 Gly Arg Glu Pro Met Val Thr Gin Arg Asn He His Ala Tyr Thr Leu 660 665 670 Cys Glu Ser Thr Arg Lys Glu Gly He Val Glu Asn Ala Asp Thr Leu 675 680 685 Thr Lys Phe Arg Arg Ser Tyr lie He Ser Arg Gly Gly Tyr He Gly 690 695 700 Asn Gin His Phe Gly Gly Met Trp Val Gly Asp Asn Ser Thr Thr Ser 705 710 715 720 Asn Tyr He Gin Met Met He Ala Asn Asn He Asn Met Asn Met Ser 725 730 735 Cys Leu Pro Leu Val Gly Ser Asp He Gly Gly Phe Thr Ser Tyr Asp 740 745 v 750 Asn Glu Asn Gin Arg Thr Pro Cys Thr Gly Asp Leu Met Val Arg Tyr 755 760 765 Val Gin Ala Gly Cys Leu Leu Pro Trp Phe Arg Asn His Tyr Asp Arg 770 775 780 Trp He Glu Ser Lys Asp His Gly Lys Asp Tyr Gin Glu Leu Tyr Met 785 790 795 800 Tyr Pro Asn Glu Met Asp Thr Leu Arg Lys Phe Val Glu Phe Arg Tyr 805 810 815 Arg Trp Gin Glu Val Leu Tyr Thr Ala Met Tyr Gin Asn Ala Ala Phe 820 825 830 Gly Lys Pro He He Lys Ala Ala Ser Met Tyr Asn Asn Asp Ser Asn 835 840 845 Val Arg Arg Ala Gin Asn Asp His Phe Leu Leu Gly Gly His Asp Gly 850 855 860 Tyr Arg He Leu Cys Ala Pro Val Val Trp Glu Asn Ser Thr Glu Arg 865 870 875 880 Glu Leu Tyr Leu Pro Val Leu Thr Gin Trp Tyr Lys Phe Gly Pro Asp 885 890 895 Phe Asp Thr Lys Pro Leu Glu Gly Ala Met Asn Gly Gly Asp Arg He 900 905 910 Tyr Asn Tyr Pro Val Pro Gin Ser Glu Ser Pro He Phe Val Arg Glu 915 920 925 Gly Ala He Leu Pro Thr Arg Tyr Thr Leu Asn Gly Glu Asn Lys Ser 930 935 940 Leu Asn Thr Tyr Thr Asp Glu Asp Pro Leu Val Phe Glu Val Phe Pro 945 950 955 960 Leu Gly Asn Asn Arg Ala Asp Gly Met Cys Tyr Leu Asp Asp Gly Gly 965 970 975 Val Thr Thr Asn Ala Glu Asp Asn Gly Lys Phe Ser Val Val Lys Val 980 985 990 Ala Ala Glu Gin Asp Gly Gly Thr Glu Thr He Thr Phe Thr Asn Asp 995 1000 1005 Cys Tyr Glu Tyr Val Phe Gly Gly Pro Phe Tyr Val Arg Val Arg Gly 1010 1015 1020 Ala Gin Ser Pro Ser Asn He His Val Ser Ser Gly Ala Gly Ser Gin 1025 1030 1035 1040 Asp Met Lys Val Ser Ser Ala Thr Ser Arg Ala Ala Leu Phe Asn Asp 1045 1050 1055 Gly Glu Asn Gly Asp Phe Trp Val Asp Gin Glu Thr Asp Ser Leu Trp 1060 1065 1070 Leu Lys Leu Pro Asn Val Val Leu Pro Asp Ala Val He Thr He Thr 1075 1080 1085 (2) INFORMATION FOR SEQ ID NO 2 (i) SEQUENCE CHARACTERISTICS (A) LENGTH 1091 amino acids (B) TYPE amino acid (D) TOPOLOGY linear (n) MOLECULE TYPE protein (xi) SEQUENCE DESCRIPTION SEQ ID NO 2 Met Tyr Pro Thr Leu Thr Phe Val Ala Pro Ser Ala Leu Gly Ala Arg 1 5 10 15 Thr Phe Thr Cys Val Gly He Phe Arg Ser His He Leu He His Ser 20 25 30 Val Val Pro Ala Val Arg Leu Ala Val Arg Lys Ser Asn Arg Leu Asn 35 40 45 Val Ser Met Ser Ala Leu Phe Asp Lys Pro Thr Ala Val Thr Gly Gly 50 55 60 Lys Asp Asn Pro Asp Asn He Asn Tyr Thr Thr Tyr Asp Tyr Val Pro 65 70 75 80 Val Trp Arg Phe Asp Pro Leu Ser Asn Thr Asn Trp Phe Ala Ala Gly 85 90 l 95 Ser Ser Thr Pro Gly Asp He Asp Asp Trp Thr Ala Thr Met Asn Val 100 105 110 Asn Phe Asp Arg He Asp Asn Pro Ser Phe Thr Leu Glu Lys Pro Val 115 120 125 Gin Val Gin Val Thr Ser Tyr Lys Asn Asn Cys Phe Arg Val Arg Phe 130 135 140 Asn Pro Asp Gly Pro He Arg Asp Val Asp Arg Gly Pro He Leu Gin 145 150 155 160 Gin Gin Leu Asn Trp He Arg Lys Gin Glu Gin Ser Lys Gly Phe Asp 165 170 175 Pro Lys Met Gly Phe Thr Lys Glu Gly Phe Leu Lys Phe Glu Thr Lys 180 185 190 Asp Leu Asn Val He He Tyr Gly Asn Phe Lys Thr Arg Val Thr Arg 195 200 205 Lys Arg Asp Gly Lys Gly He Met Glu Asn Asn Glu Val Pro Ala Gly 210 215 220 Ser Leu Gly^sn Lys Cys Arg Gly Leu Met Phe Val Asp Arg Leu Tyr 225 230 235 240 Gly Thr Ala He Ala Ser Val Asn Glu Asn Tyr Arg Asn Asp Pro Asp 245 250 255 Arg Lys Glu Gly Phe Tyr Gly Ala Gly Glu Val Asn Cys Glu Phe Trp 260 265 270 Asp Ser Glu Gin Asn Arg Asn Lys Tyr He Leu Glu Arg Thr Gly He 275 280 285 Ala Met Thr Asn Tyr Asn Tyr Asp Asn Tyr Asn Tyr Asn Gin Ser Asp 290 295 300 Leu He Ala Pro Gly Tyr Pro Ser Asp Pro Asn Phe Tyr He Pro Met 305 310 315 320 Tyr Phe Ala Ala Pro Trp Val Val Val Lys Gly Cys Ser Gly Asn Ser 325 330. 335 Asp Glu Gin Tyr Ser Tyr Gly Trp Phe Met Asp Asn Val Ser Gin Thr 340 345 350 Tyr Met Asn Thr Gly Gly Thr Ser Trp Asn Cys Gly Glu Glu Asn Leu 355 360 365 Ala Tyr Met Gly Ala Gin Cys Gly Pro Phe Asp Gin His Phe Val Tyr 370 375 380 Gly Asp Gly Asp Gly Leu Glu Asp Val Val Gin Ala Phe Ser Leu Leu 385 390 395 400 Gin Gly Lys Glu Phe Glu Asn Gin Val Leu Asn Lys Arg Ala Val Met 405 410 415 Pro Pro Lys Tyr Val Phe Gly Tyr Phe Gin Gly Val Phe Gly He Ala 420 425 430 Ser Leu Leu Arg Glu Gin Arg Pro Glu Gly Gly Asn Asn He Ser Val 435 440 445 Gin Glu He Val Glu Gly Tyr Gin Ser Asn Asn Phe Pro Leu Glu Gly 450 455 460 Leu Ala Val Asp Val Asp Met Gin Gin Asp Leu Arg Val Phe Thr Thr 465 470 475 480 Lys He Glu Phe Trp Thr Ala Asn Lys Val Gly Thr Gly Gly Asp Ser 485 490 495 Asn Asn Lys Ser Val Phe Glu Trp Ala His Asp Lys Gly Leu Val Cys 500 505 510 Gin Thr Asn Val Thr Cys Phe Leu Arg Asn Asp Asn Gly Gly Ala Asp 515 520 525 Tyr Glu Val Asn Gin Thr Leu Arg Glu Lys Gly Leu Tyr Thr Lys Asn 530 535 540 Asp Ser Leu Thr Asn Thr Asn Phe Gly Thr Thr Asn Asp Gly Pro Ser 545 550 555 560 Asp Ala Tyr He Gly His Leu Asp Tyr Gly Gly Gly Gly Asn Cys Asp 565 570 575 Ala Leu Phe Pro Asp Trp Gly Arg Pro Gly Val Ala Glu Trp Trp Gly 580 585 590 Asp Asn Tyr Ser Lys Leu Phe Lys He Gly Leu Asp Phe Val Trp Gin 595 600 605 Asp Met Thr Val Pro Ala Met Met Pro His Lys Val Gly Asp Ala Val 610 615 620 Asp Thr Arg Ser Pro Tyr Gly Trp Pro Asn Glu Asn Asp Pro Ser Asn 625 630 635 640 Gly Arg Tyr Asn Trp Lys Ser Tyr His Pro Gin Val Leu Val Thr Asp 645 650 655 Met Arg Tyr Glu Asn His Gly Arg Glu Pro Met Phe Thr Gin Arg Asn 660 665 670 Met His Ala Tyr Thr Leu Cys Glu Ser Thr Arg Lys Glu Gly He Val 675 680 685 Ala Asn Ala Asp Thr Leu Thr Lys Phe Arg Arg Ser Tyr He He Ser 690 695 700 Arg Gly Gly Tyr He Gly Asn Gin His Phe Gly Gly Met Trp Val Gly 705 710 715 720 Asp Asn Ser Ser Ser Gin Arg Tyr Leu Gin Met Met He Ala Asn He 725 730 735 Val Asn Met Asn Met Ser Cys Leu Pro Leu Val Gly Ser Asp He Gly 740 745 750 Gly Phe Thr-Ser Tyr Asp Gly Arg Asn Val Cys Pro Gly Asp Leu Met 755 760 765 Val Arg Phe Val Gin Ala Gly Cys Leu Leu Pro Trp Phe Arg Asn His 770 775 780 Tyr Gly Arg Leu Val Glu Gly Lys Gin Glu Gly Lys Tyr Tyr Gin Glu 785 790 795 800 Leu Tyr Met Tyr Lys Asp Glu Met Ala Thr Leu Arg Lys Phe He Glu 805 810 815 Phe Arg Tyr Arg Trp Gin Glu Val Leu Tyr Thr Ala Met Tyr Gin Asn 820 825 830 Ala Ala Phe Gly Lys Pro He He Lys Ala Ala Ser Met Tyr Asp Asn 835 840 845 Asp Arg Asn Val Arg Gly Ala Gin Asp Asp His Phe Leu Leu Gly Gly 850 855 860 His Asp Gly Tyr Arg He Leu Cys Ala Pro Val Val Trp Glu Asn Thr 865 870 875 880 Thr Ser Arg Asp Leu Tyr Leu Pro Val Leu Thr Lys Trp Tyr Lys Phe 885 890 895 Gly Pro Asp Tyr Asp Thr Lys Arg Leu Asp Ser Ala Leu Asp Gly Gly 900 905 910 Gin Met He Lys Asn Tyr Ser Val Pro Gin Ser Asp Ser Pro He Phe 915 920 925 Val Arg Glu Gly Ala He Leu Pro Thr Arg Tyr Thr Leu Asp Gly Ser 930 935 940 Asn Lys Ser Met Asn Thr Tyr Thr Asp Lys Asp Pro Leu Val Phe Glu 945 950 955 960 Val Phe Pro Leu Gly Asn Asn Arg Ala Asp Gly Met Cys Tyr Leu Asp 965 970 975 Asp Gly Gly He Thr Thr Asp Ala Glu Asp His Gly Lys Phe Ser Val 980 985 990 He Asn Val Glu Ala Leu Arg Lys Gly Val Thr Thr Thr He Lys Phe 995 1000 1005 Ala Tyr Asp Thr Tyr Gin Tyr Val Phe Asp Gly Pro Phe Tyr Val Arg 1010 1015 1020 He Arg Asn Leu Thr Thr Ala Ser Lys He Asn Val Ser Ser Gly Ala 1025 1030 1035 1040 Gly Glu Glu Asp Met Thr Pro Thr Ser Ala Asn Ser Arg Ala Ala Leu 1045 1050 1055 Phe Ser Asp Gly Gly Val Gly Glu Tyr Trp Ala Asp Asn Asp Thr Ser 1060 1065 1070 Ser Leu Trp Met Lys Leu Pro Asn Leu Val Leu Gin Asp Ala Val He 1075 1080 1085 Thr He Thr 1090 (2) INFORMATION FOR SEQ ID NO 3 (i) SEQUENCE CHARACTERISTICS (A) LENGTH 1066 amino acids (B) TYPE amino acid (D) TOPOLOGY linear (n) MOLECULE TYPE protein (xi) SEQUENCE DESCRIPTION SEQ ID NO 3 Met Ala Gly Phe Ser Asp Pro Leu Asn Phe Cys Lys Ala Glu Asp Tyr 1 5 10 15 Tyr Ser Val Ala Leu Asp Trp Lys Gly Pro Gin Lys He He Gly Val 20 25 30 Asp Thr Thr Pro Pro Lys Ser Thr Lys Phe Pro Lys Asn Trp His Gly 35 40 45 Val Asn Leu Arg Phe Asp Asp Gly Thr Leu Gly Val Val Gin Phe He 50 55 60 Arg Pro Cys Val Trp Arg Val Arg Tyr Asp Pro Gly Phe Lys Thr Ser 65 70 75 80 Asp Glu Tyr-Gly Asp Glu Asn Thr Arg Thr He Val Gin Asp Tyr Met 85 90 95 Ser Thr Leu Ser Asn Lys Leu Asp Thr Tyr Arg Gly Leu Thr Trp Glu 100 105 110 Thr Lys Cys Glu Asp Ser Gly Asp Phe Phe Thr Phe Ser Ser Lys Val 115 120 125 Thr Ala Val Glu Lys Ser Glu Arg Thr Arg Asn Lys Val Gly Asp Gly 130 135 140 Leu Arg He His Leu Trp Lys Ser Pro Phe Arg He Gin Val Val Arg 145 150 155 160 Thr Leu Thr Pro Leu Lys Asp Pro Tyr Pro He Pro Asn Val Ala Ala 165 170 175 Ala Glu Ala Arg Val Ser Asp Lys Val Val Trp Gin Thr Ser Pro Lys 180 185 190 Thr Phe Arg Lys Asn Leu His Pro Gin His Lys Met Leu Lys Asp Thr 195 200 205 Val Leu Asp He Val Lys Pro Gly His Gly Glu Tyr Val Gly Trp Gly 210 215 220 Glu Met Gly Gly He Gin Phe Met Lys Glu Pro Thr Phe Met Asn Tyr 225 230 235 240 Phe Asn Phe Asp Asn Met Gin Tyr Gin Gin Val Tyr Ala Gin Gly Ala 245 250 255 Leu Asp Ser Arg Glu Pro Leu Tyr His Ser Asp Pro Phe Tyr Leu Asp 260 265 270 Val Asn Ser Asn Pro Glu His Lys Asn He Thr Ala Thr Phe He Asp 275 280 285 Asn Tyr Ser Gin He Ala He Asp Phe Gly Lys Thr Asn Ser Gly Tyr 290 295 300 He Lys Leu Gly Thr Arg Tyr Gly Gly He Asp Cys Tyr Gly He Ser 305 310 315 320 Ala Asp Thr Val Pro Glu He Val Arg Leu Tyr Thr Gly Leu Val Gly 325 330 335 Arg Ser Lys Leu Lys Pro Arg Tyr He Leu Gly Ala His Gin Ala Cys 340 345 350 Tyr Gly Tyr Gin Gin Glu Ser Asp Leu Tyr Ser Val Val Gin Gin Tyr 355 360 365 Arg Asp Cys Lys Phe Pro Leu Asp Gly He His Val Asp Val Asp Val 370 375 380 Gin Asp Gly Phe Arg Thr Phe Thr Thr Asn Pro His Thr Phe Pro Asn 385 390 395 400 Pro Lys Glu Met Phe Thr Asn Leu Arg Asn Asn Gly He Lys Cys Ser 405 410 415 Thr Asn He Thr Pro Val He Ser He Asn Asn Arg Glu Gly Gly Tyr 420 425 430 Ser Thr Leu Leu Glu Gly Val Asp Lys Lys Tyr Phe He Met Asp Asp 435 440 445 Arg Tyr Thr Glu Gly Thr Ser Gly Asn Ala Lys Asp Val Arg Tyr Met 450 455 460 Tyr Tyr Gly Gly Gly Asn Lys Val Glu Val Asp Pro Asn Asp Val Asn 465 470 475 v 480 Gly Arg Pro Asp Phe Lys Asp Asn Tyr Asp Phe Pro Ala Asn Phe Asn 485 490 495 Ser Lys Gin Tyr Pro Tyr His Gly Gly Val Ser Tyr Gly Tyr Gly Asn 500 505 510 Gly Ser Ala Gly Phe Tyr Pro Asp Leu Asn Arg Lys Glu Val Arg He 515 520 525 Trp Trp Gly Met Gin Tyr Lys Tyr Leu Phe Asp Met Gly Leu Glu Phe 530 535 540 Val Trp Gin Asp Met Thr Thr Pro Ala He His Thr Ser Tyr Gly Asp 545 550 555 560 Met Lys Gly Leu Pro Thr Arg Leu Leu Val Thr Ser Asp Ser Val Thr 565 570 575 Asn Ala Ser Glu Lys Lys Leu Ala He Glu Thr Trp Ala Leu Tyr Ser 580 585 590 Tyr Asn Leu His Lys Ala Thr Trp His Gly Leu Ser Arg Leu Glu Ser 595 600 605 Arg Lys As - Lys Arg Asn Phe He Leu Gly Arg Gly Ser Tyr Ala Gly 610 615 620 Ala Tyr Arg Phe Ala Gly Leu Trp Thr Gly Asp Asn Ala Ser Asn Trp 625 630 635 640 Glu Phe Trp Lys He Ser Val Ser Gin Val Leu Ser Leu Gly Leu Asn 645 650 655 Gly Val Cys He Ala Gly Ser Asp Thr Gly Gly Phe Glu Pro Tyr Arg 660 665 670 Asp Ala Asn Gly Val Glu Glu Lys Tyr Cys Ser Pro Glu Leu Leu He 675 680 685 Arg Trp Tyr Thr Gly Ser Phe Leu Leu Pro Trp Leu Arg Asn His Tyr 690 695 700 Val Lys Lys Asp Arg Lys Trp Phe Gin Glu Pro Tyr Ser Tyr Pro Lys 705 710 715 720 His Leu Glu Thr His Pro Glu Leu Ala Asp Gin Ala Trp Leu Tyr Lys 725 730 735 Ser Val Leu Glu He Cys Arg Tyr Tyr Val Glu Leu Arg Tyr Ser Leu 740 745 750 He Gin Leu Leu Tyr Asp Cys Met Phe Gin Asn Val Val Asp Gly Met 755 760 765 Pro He Thr Arg Ser Met Leu Leu Thr Asp Thr Glu Asp Thr Thr Phe 770 775 780 Phe Asn Glu Ser Gin Lys Phe Leu Asp Asn Gin Tyr Met Ala Gly Asp 785 790 795 800 Asp He Leu Val Ala Pro He Leu His Ser Arg Lys Glu He Pro Gly 805 810 815 Glu Asn Arg Asp Val Tyr Leu Pro Leu Tyr His Thr Trp Tyr Pro Ser 820 825 830 Asn Leu Arg Pro Trp Asp Asp Gin Gly Val Ala Leu Gly Asn Pro Val 835 840 845 Glu Gly Gly Ser Val He Asn Tyr Thr Ala Arg He Val Ala Pro Glu 850 855 860 Asp Tyr Asn Leu Phe His Ser Val Val Pro Val Tyr Val Arg Glu Gly 865 870 875 880 Ala He He Pro Gin He Glu Val Arg Gin Trp Thr Gly Gin Gly Gly 885 890 895 Ala Asn Arg He Lys Phe Asn He Tyr Pro Gly Lys Asp Lys Glu Tyr 900 905 910 Cys Thr Tyr Leu Asp Asp Gly Val Ser Arg Asp Ser Ala Pro Glu Asp 915 920 925 Leu Pro Gin Tyr Lys Glu Thr His Glu Gin Ser Lys Val Glu Gly Ala 930 935 940 Glu He Ala Lys Gin He Gly Lys Lys Thr Gly Tyr Asn He Ser Gly 945 950 955 960 Thr Asp Pro Glu Ala Lys Gly Tyr His Arg Lys Val Ala Val Thr Gin 965 970 975 Thr Ser Lys Asp Lys Thr Arg Thr Val Thr He Glu Pro Lys His Asn 980 985 990 Gly Tyr Asp Pro Ser Lys Glu Val Gly Asp Tyr Tyr Thr He He Leu 995 1000 1005 Trp Tyr Ala Pro Gly Phe Asp Gly Ser He Val Asp Val Ser Lys Thr 1010 1015 1020 Thr Val Asn Val Glu Gly Gly Val Glu His Gin Val Tyr Lys Asn Ser 1025 1030 1035 1040 Asp Leu His Thr Val Val He Asp Val Lys Glu Val He Gly Thr Thr 1045 1050 1055 Lys Ser Val Lys He Thr Cys Thr Ala Ala 1060 1065 (2) INFORMATION EOR SEQ ID NO 4 (i) SEQUENCE CHARACTERISTICS' (A) LENGTH 1070 amino acids (B) TYPE amino acid (D) TOPOLOGY linear (n) MOLECULE TYPE protein (xi) SEQUENCE DESCRIPTION SEQ ID NO 4 Met Ala Gly Leu Ser Asp Pro Leu Asn Phe Cys Lys Ala Glu Asp Tyr 1 5 10 15 Tyr Ala Ala Ala Lys Gly Trp Ser Gly Pro Gin Lys He He Arg Tyr 20 25 30 Asp Gin Thr Pro Pro Gin Gly Thr Lys Asp Pro Lys Ser Trp His Ala 35 40 45 Val Asn Leu Pro Phe Asp Asp Gly Thr Met Cys Val Val Gin Phe Val 50 55 60 Arg Pro Cys Val Trp Arg Val Arg Tyr Asp Pro Ser Val Lys Thr Ser 65 70 75 80 Asp Glu Tyr Gly Asp Glu Asn Thr Arg Thr He Val Gin Asp Tyr Met 85 90 95 Thr Thr Leu Val Gly Asn Leu Asp He Phe Arg Gly Leu Thr Trp Val 100 105 110 Ser Thr Leu Glu Asp Ser Gly Glu Tyr Tyr Thr Phe Lys Ser Glu Val 115 120 125 Thr Ala Val Asp Glu Thr Glu Arg Thr Arg Asn Lys Val Gly Asp Gly 130 135 140 Leu Lys He Tyr Leu Trp Lys Asn Pro Phe Arg He Gin Val Val Arg 145 150 155 160 Leu Leu Thr Pro Leu Val Asp Pro Phe Pro He Pro Asn Val Ala Asn 165 170 175 Ala Thr Ala Arg Val Ala Asp Lys Val Val Trp Gin Thr Ser Pro Lys 180 185 190 Thr Phe Arg Lys Asn Leu His Pro Gin His Lys Met Leu Lys Asp Thr 195 200 205 Val Leu Asp He He Lys Pro Gly His Gly Glu Tyr Val Gly Trp Gly 210 215 220 Glu Met Gly Gly He Glu Phe Met Lys Glu Pro Thr Phe Met Asn Tyr 225 230 235 240 Phe Asn Phe Asp Asn Met Gin Tyr Gin Gin Val Tyr Ala Gin Gly Ala 245 250 255 Leu Asp Ser Arg Glu Pro Leu Tyr His Ser Asp Pro Phe Tyr Leu Asp 260 265 270 Val Asn Ser Asn Pro Glu His Lys Asn He Thr Ala Thr Phe He Asp 275 280 285 Asn Tyr Ser Gin He Ala He Asp Phe Gly Lys Thr Asn Ser Gly Tyr 290 295 300 He Lys Leu Gly Thr Arg Tyr Gly Gly He Asp Cys Tyr Gly He Ser 305 310 315 320 Ala Asp Thr Val Pro Glu He Val Arg Leu Tyr Thr Gly Leu Val Gly 325 330 335 Arg Ser Lys Leu Lys Pro Arg Tyr He Leu Gly Ala His Gin Ala Cys 340 345 350 Tyr Gly Tyr Gin Gin Glu Ser Asp Leu His Ala Val Val Gin Gin Tyr 355 360 365 Arg Asp Thr Lys Phe Pro Leu Asp Gly Leu His Val Asp Val Asp Phe 370 375 380 Gin Asp Asn Phe Arg Thr Phe Thr Thr Asn Pro He Thr Phe Pro Asn 385 390 395 400 Pro Lys Glu Met Phe Thr Asn Leu Arg Asn Asn Gly He Lys Cys Ser 405 410 415 Thr Asn He Thr Pro Val He Ser He Arg Asp Arg Pro Asn Gly Tyr 420 425 430 Ser Thr Leu Asn Glu Gly Tyr Asp Lys Lys Tyr Phe He Met Asp Asp 435 440 445 Arg Tyr Thr.Glu Gly Thr Ser Gly Asp Pro Gin Asn Val Arg Tyr Ser 450 455 460 Phe Tyr Gly Gly Gly Asn Pro Val Glu Val Asn Pro Asn Asp Val Trp 465 470 475 480 Ala Arg Pro Asp Phe Gly Asp Asn Tyr Asp Phe Pro Thr Asn Phe Asn 485 490 495 Cys Lys Asp Tyr Pro Tyr His Gly Gly Val Ser Tyr Gly Tyr Gly Asn 500 505 510 Gly Thr Pro Gly Tyr Tyr Pro Asp Leu Asn Arg Glu Glu Val Arg He 515 ϊ 520 525 Trp Trp Gly Leu Gin Tyr Glu Tyr Leu Phe Asn Met Gly Leu Glu Phe 530 535 540 Val Trp Gin Asp Met Thr Thr Pro Ala He His Ser Ser Tyr Gly Asp 545 550 555 560 Met Lys Gly Leu Pro Thr Arg Leu Leu Val Thr Ala Asp Ser Val Thr 565 570 575 Asn Ala Ser Glu Lys Lys Leu Ala He Glu Ser Trp Ala Leu Tyr Ser 580 585 590 Tyr Asn Leu His Lys Ala Thr Phe His Gly Leu Gly Arg Leu Glu Ser 595 600 605 Arg Lys Asn Lys Arg Asn Phe He Leu Gly Arg Gly Ser Tyr Ala Gly 610 615 620 Ala Tyr Arg Phe Ala Gly Leu Trp Thr Gly Asp Asn Ala Ser Thr Trp 625 630 635 640 Glu Phe Trp Lys He Ser Val Ser Gin Val Leu Ser Leu Gly Leu Asn 645 650 655 Gly Val Cys He Ala Gly Ser Asp Thr Gly Gly Phe Glu Pro Ala Arg 660 665 670 Thr Glu He Gly Glu Glu Lys Tyr Cys Ser Pro Glu Leu Leu He Arg 675 680 685 Trp Tyr Thr Gly Ser Phe Leu Leu Pro Trp Leu Arg Asn His Tyr Val 690 695 700 Lys Lys Asp Arg Lys Trp Phe Gin Glu Pro Tyr Ala Tyr Pro Lys His 705 710 715 720 Leu Glu Thr His Pro Glu Leu Ala Asp Gin Ala Trp Leu Tyr Lys Ser 725 730 735 Val Leu Glu He Cys Arg Tyr Trp Val Glu Leu Arg Tyr Ser Leu He 740 745 750 Gin Leu Leu Tyr Asp Cys Met Phe Gin Asn Val Val Asp Gly Met Pro 755 760 765 Leu Ala Arg Ser Met Leu Leu Thr Asp Thr Glu Asp Thr Thr Phe Phe 770 775 780 Asn Glu Ser Gin Lys Phe Leu Asp Asn Gin Tyr Met Ala Gly Asp Asp 785 790 795 800 He Leu Val Ala Pro He Leu His Ser Arg Asn Glu Val Pro Gly Glu 805 810 815 Asn Arg Asp Val Tyr Leu Pro Leu Phe His Thr Trp Tyr Pro Ser Asn 820 825 830 Leu Arg Pro Trp Asp Asp Gin Gly Val Ala Leu Gly Asn Pro Val Glu 835 840 845 Gly Gly Ser Val He Asn Tyr Thr Ala Arg He Val Ala Pro Glu Asp 850 855 860 Tyr Asn Leu Phe His Asn Val Val Pro Val Tyr He Arg Glu Gly Ala 865 870 875 880 He He Pro Gin He Gin Val Arg Gin Trp He Gly Glu Gly Gly Pro 885 890 895 Asn Pro He Lys Phe Asn He Tyr Pro Gly Lys Asp Lys Glu Tyr Val 900 905 910 Thr Tyr Leu Asp Asp Gly Val Ser Arg Asp Ser Ala Pro Asp Asp Leu 915 920 925 Pro Gin Tyr Arg Glu Ala Tyr Glu Gin Ala Lys Val Glu Gly Lys Asp 930 935 940 Val Gin Lys Gin Leu Ala Val He Gin Gly Asn Lys Thr Asn Asp Phe 945 950 955 960 Ser Ala Ser Gly He Asp Lys Glu Ala Lys Gly Tyr His Arg Lys Val 965 970 975 Ser He Lys.Gin Glu Ser Lys Asp Lys Thr Arg Thr Val Thr He Glu 980 985 990 Pro Lys His Asn Gly Tyr Asp Pro Ser Lys Glu Val Gly Asn Tyr Tyr 995 1000 1005 Thr He He Leu Trp Tyr Ala Pro Gly Phe Asp Gly Ser He Val Asp 1010 1015 1020 Val Ser Gin Ala Thr Val Asn He Glu Gly Gly Val Glu Cys Glu He 1025 1030 1035 1040 Phe Lys Asn Thr Gly Leu His Thr Val Val Val Asn Val Lys Glu Val 1045 1050 1055 He Gly Thr Thr Lys Ser Val Lys He Thr Cys Thr Thr Ala 1060 1065 1070 SEQ. ID. NO. 5 SEQUENCE TYPE: ENZYME MOLECULE TYPE: AMINO ACID ORIGINAL SOURCE: ALGAL SEQUENCE LENGTH: 1092 AMINO ACIDS SEQUENCE: 5 10 15 1 1 1 Met Phe Pro Thr Leu Thr Phe He Ala Pro Ser Ala Leu Ala Ala 16 Ser Thr Phe Val Gly Ala Asp He Arg Ser Gly He Arg He Gin 31 Ser Ala Leu Pro Ala Val Arg Asn Ala Val Arg Arg Ser Lys His 46 Tyr Asn Val Ser Met Thr Ala Leu Ser Asp Lys Gin Thr Ala He 61 Ser He Gly Pro Asp Asn Pro Asp Gly He Asn Tyr Gin Asn Tyr 76 Asp Tyr He Pro Val Ala Gly Phe Thr Pro Leu Ser Asn Thr Asn 91 Trp Tyr Ala Ala Gly Ser Ser Thr Pro Gly Gly He Thr Asp Trp 106 Thr Ala Thr Met Asn Val Lys Phe Asp Arg He Asp Asn Pro Ser 121 Tyr Ser Asn Asn His Pro Val Gin He Gin Val Thr Ser Tyr Asn 136 Asn Asn Ser Phe Arg He Arg Phe Asn Pro Asp Gly Pro He Arg 151 Asp Val Ser Arg Gly Pro He Leu Lys Gin Gin Leu Thr Trp He 166 Arg Asn Gin Glu Leu Ala Gin Gly Cys Asn Pro Asn Met Ser Phe 181 Ser Pro Glu Gly Phe Leu Ser Phe Glu Thr Lys Asp Leu Asn Val 196 He He Tyr Gly Asn Cys Lys Met Arg Val Thr Lys Lys Asp Gly 211 Tyr Leu Val Met Glu Asn Asp Glu Cys Asn Ser Gin Ser Asp Gly 226 Asn Lys Cys Arg Gly Leu Met Tyr Val Asp Arg Leu Tyr Gly Asn 241 Ala He Ala Ser Val Gin Thr Asn Phe His Lys Asp Thr Ser Arg 256 Asn Glu Lys Phe Tyr Gly Ala Gly Glu Val Asn Cys Arg Tyr Glu 271 Glu Gin Gly Lys Ala Pro Thr Tyr Val Leu Glu Arg Ser Gly Leu 286 Ala Met Thr Asn Tyr Asn Tyr Asp Asn Leu Asn Tyr Asn Gin Pro 301 Asp Val Val Pro Pro Gly Tyr Pro Asp His Pro Asn Tyr Tyr He 316 Pro Met Tyr Tyr Ala Ala Pro Trp Leu Val Val Gin Gly Cys Ala 331 Gly Thr Ser Lys Gin Tyr Ser Tyr Gly Trp Phe Met Asp Asn Val 346 Ser Gin Ser Tyr Met Asn Thr Gly Asp Thr Ala Trp Asn Cys Gly 361 Gin Glu Asn Leu Ala Tyr Met Gly Ala Gin Tyr Gly Pro Phe Asp 376 Gin His Phe Val Tyr Gly Asp Gly Asp Gly Leu Glu Asp Val Val 391 Lys Ala Phe Ser Phe Leu Gin Gly Lys Glu Phe Glu Asp Lys Lys 406 Leu Asn Lys Arg Ser Val Met Pro Pro Lys Tyr Val Phe Gly Phe 421 Phe Gin Gly Val Phe Gly Ala Leu Ser Leu Leu Lys Gin Asn Leu 436 Pro Ala Gly Glu Asn Asn He Ser Val Gin Glu He Val Glu Gly 451 Tyr Gin Asp Asn Asp Tyr Pro Phe Glu Gly Leu Ala Val Asp Val 466 Asp Met Gin Asp Asp Leu Arg Val Phe Thr Thr Lys Pro Glu Tyr 481 Trp Ser Ala Asn Met Val Gly Glu Gly Gly Asp Pro Asn Asn Arg 496 Ser Val Phe Glu Trp Ala His Asp Arg Gly Leu Val Cys Gin Thr 511 Asn Val Thr Cys Phe Leu Arg Asn Asp Asn Ser Gly Lys Pro Tyr 526 Glu Val Asn Gin Thr Leu Arg Glu Lys Gin Leu Tyr Thr Lys Asn 541 Asp Ser Leu Asn Asn Thr Asp Phe Gly Thr Thr Ser Asp Gly Pro 556 Gly Asp Ala Tyr He Gly His Leu Asp Tyr Gly Gly Gly Val Glu 571 Cys Asp Ala He Phe Pro Asp Trp Gly Arg Pro Asp Val Ala Gin 586 Trp Trp Gly Glu Asn Tyr Lys Lys Leu Phe Ser He Gly Leu Asp 601 Phe Val Trp Gin Asp Met Thr Val Pro Ala Met Met Pro His Arg 616 Leu Gly Asp Ala Val Asn Lys Asn Ser Gly Ser Ser Ala Pro Gly 631 Trp Pro Asn Glu Asn Asp Pro Ser Asn Gly Arg Tyr Asn Trp Lys 646 Ser Tyr His Pro Gin Val Leu Val Thr Asp Met Arg Tyr Gly Ala 661 Glu Tyr Gly Arg Glu Pro Met Val Ser Gin Arg Asn He His Ala 676 Tyr Thr Leu Cys Glu Ser Thr Arg-Arg Glu Gly He Val Gly Asn 691 Ala Asp Ser Leu Thr Lys Phe Arg Arg Ser Tyr He He Ser Arg 706 Gly Gly Tyr He Gly Asn Gin His Phe Gly Gly Met Trp Val Gly 721 Asp Asn Ser Ala Thr Glu Ser Tyr Leu Gin Met Met Leu Ala Asn 736 He He Asn Met Asn Met Ser Cys Leu Pro Leu Val Gly Ser Asp 751 He Gly Gly Phe Thr Gin Tyr Asn Asp Ala Gly Asp Pro Thr Pro 766 Glu Asp Leu Met Val Arg Phe Val Gin Ala Gly Cys Leu Leu Pro 781 Trp Phe Arg Asn His Tyr Asp Arg Trp He Glu Ser Lys Lys His 796 Gly Lys Lys Tyr Gin Glu Leu Tyr Met Tyr Pro Gly Gin Lys Asp 811 Thr Leu Lys Lys Phe Val Glu Phe Arg Tyr Arg Trp Gin Glu Val 826 Leu Tyr Thr Ala Met Tyr Gin Asn Ala Thr Thr Gly Glu Pro He 841 He Lys Ala Ala Pro Met Tyr Asn Asn Asp Val Asn Val Tyr Lys 856 Ser Gin Asn Asp His Phe Leu Leu Gly Gly His Asp Gly Tyr Arg 871 He Leu Cys Ala Pro Val Val Arg Glu Asn Ala Thr Ser Arg Glu 886 Val Tyr Leu Pro Val Tyr Ser Lys Trp Phe Lys Phe Gly Pro Asp 901 Phe Asp Thr Lys Pro Leu Glu Asn Glu He Gin Gly Gly Gin Thr 916 Leu Tyr Asn Tyr Ala Ala Pro Leu Asn Asp Ser Pro He Phe Val 931 Arg Glu Gly Thr He Leu Pro Thr Arg Tyr Thr Leu Asp Gly Val 946 Asn Lys Ser He Asn Thr Tyr Thr Asp Asn Asp Pro Leu Val Phe 961 Glu Leu Phe Pro Leu Glu Asn Asn Gin Ala His Gly Leu Phe Tyr 976 His Asp Asp Gly Gly Val Thr Thr Asn Ala Glu Asp Phe Gly Lys 991 Tyr Ser Val He Ser Val Lys Ala Ala Gin Glu Gly Ser Gin Met 1006 Ser Val Lys Phe Asp Asn Glu Val Tyr Glu His Gin Trp Gly Ala 1021 Ser Phe Tyr Val Arg Val Arg Asn Met Gly Ala Pro Ser Asn He 1036 Asn Val Ser Ser Gin He Gly Gin Gin Asp Met Gin Gin Ser Ser 1051 Val Ser Ser Arg Ala Gin Met Phe Thr Ser Ala Asn Asp Gly Glu 1066 Tyr Trp Val Asp Gin Ser Thr Asn Ser Leu Trp Leu Lys Leu Pro 1081 Gly Ala Val He Gin Asp Ala Ala He Thr Val Arg Number of amino acid residues. 1092 Amino acid composition (including the signal sequense). 64 Ala 14 Cys 18 His 33 Met 56 Thr 48 Arg 55 Gin 45 He 49 Phe 22 Trp 89 Asn 49 Glu 65 Leu 59 Pro 67 Tyr 73 Asp 94 Gly 46 Lys 73 Ser 73 Val SEQ. ID. NO. 6 SEQUENCE TYPE: ENZYME MOLECULE TYPE AMINO ACID ORIGINAL SOURCE ALGAL SEQUENCE LENGTH. 570 AMINO ACIDS SEQUENCE- 5 10 15 I I I I I I 1 Met Thr Asn Tyr Asn Tyr Asp Asn Leu Asn Tyr Asn Gin Pro Asp 16 Leu He Pro Pro Gly His Asp Ser Asp Pro Asp Tyr Tyr He Pro 31 Met Tyr Phe Ala Ala Pro Trp Val He Ala His Gly Tyr Arg Gly 46 Thr Ser Asp Gin Tyr Ser Tyr Gly Trp Phe Leu Asp Asn Val Ser 61 Gin Ser Tyr Thr Asn Thr Gly Asp Asp Ala Trp Ala Gly Gin Lys 76 Asp Leu Ala Tyr Met Gly Ala Gin Cys Gly Pro Phe Asp Gin His 91 Phe Val Tyr Glu Ala Gly Asp Gly Leu Glu Asp Val Val Thr Ala 106 Phe Ser Tyr Leu Gin Gly Lys Glu Tyr Glu Asn Gin Gly Leu Asn 121 He Arg Ser Ala Met Pro Pro Lys Tyr Val Phe Gly Phe Phe Gin 136 Gly Val Phe Gly Ala Thr Ser Leu Leu Arg Asp Asn Leu Pro Ala 151 Gly Glu Asn Asn Val Ser Leu Glu Glu He Val Glu Gly Tyr Gin 166 Asn Gin Asn Val Pro Phe Glu Gly Leu Ala Val Asp Val Asp Met 181 Gin Asp Asp Leu Arg Val Phe Thr Thr Arg Pro Ala Phe Trp Thr 196 Ala Asn Lys Val Gly Glu Gly Gly Asp Pro Asn Asn Lys Ser Val 211 Phe Glu Trp Ala His Asp Arg Gly Leu Val Cys Gin Thr Asn Val 226 Thr Cys Phe Leu Lys Asn Glu Lys Asn Pro Tyr Glu Val Asn Gin 241 Ser Leu Arg Glu Lys Gin Leu Tyr Thr Lys Ser Asp Ser Leu Asp 256 Asn He Asp Phe Gly Thr Thr Pro Asp Gly Pro Ser Asp Ala Tyr 271 He Gly H s Leu Asp Tyr Gly Gly Gly Val Glu Cys Asp Ala Leu 286 Phe Pro Asp Trp Gly Arg Pro Asp Val Ala Gin Trp Trp Gly Asp 301 Asn Tyr Lys Lys Leu Phe Ser H e Gly Leu Asp Phe Val Trp Gi n 316 Asp Met Thr Val Pro Ala Met Met Pro Hi s Arg Leu Gly Asp Pro 331 Val Gly Thr Asn Ser Gly Glu Thr Al a Pro Gly Trp Pro Asn Asp 346 Lys Asp Pro Ser Asn Gly Arg Tyr Asn Trp Lys Ser Tyr Hi s Pro 361 Gin Val Leu Val Thr Asp Met Arg Tyr Asp Asp Tyr Gly Arg Asp 376 Pro He Val Thr Gin Arg Asn Leu Hi s Al a Tyr Thr Leu Cys Gl u 391 Ser Thr Arg Arg Glu Gly He Val Gly Asn Al a Asp Ser Leu Thr 406 Lys Phe Arg Arg Ser Tyr He H e Ser Arg Gly Gly Tyr H e Gly 421 Asn Gin His Phe Gly Gly Met Trp Val Gly Asp Asn Ser Ser Thr 436 Glu Asp Tyr Leu Ala Met Met Val H e Asn Val H e Asn Met Asn 451 Met Ser Gly Val Pro Leu Val Gly Ser Asp He Gly Gly Phe Thr 466 Glu His Asp Lys Arg Asn Pro Cys Thr Pro Asp Leu Met Met Arg 481 Phe Val Gin Ala Gly Cys Leu Leu Pro Trp Phe Arg Asn Hi s Tyr 496 Asp Arg Trp He Glu Ser Lys Lys Hi s Gly Lys Asn Tyr Gi n Gl u 511 Leu Tyr Met Tyr Arg Asp His Leu Asp Al a Leu Arg Ser Phe Val 526 Glu Leu Arg Tyr Arg Trp Gin Gl u Val Leu Tyr Thr Al a Met Tyr 541 Gin Asn Ala Leu Asn Gly Lys Pro H e H e Lys Thr Val Ser Met 556 Tyr Asn Asn Asp Met Asn Val Lys Asp Al a Gi n Asn Asp H s Phe (2) INFORMATION FOR SEQ ID NO. 7. (i) SEQUENCE CHARACTERISTICS. (A) LENGTH: 3267 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (n) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: ATGTTTTCAA CCCTTGCGTT TGTCGCACCT AGTGCGCTGG GAGCCAGTAC CTTCGTAGGG 60 GCGGAGGTCA GGTCAAATGT TCGTATCCAT TCCGCTTTTC CAGCTGTGCA CACAGCTACT 120 CGCAAAACCA ATCGCCTCAA TGTATCCATG ACCGCATTGT CCGACAAACA AACGGCTACT 180 GCGGGTAGTA CAGACAATCC GGACGGTATC GACTACAAGA CCTACGATTA CGTCGGAGTA 240 TGGGGTTTCA GCCCCCTCTC CAACACGAAC TGGTTTGCTG CCGGCTCTTC TACCCCGGGT 300 GGCATCACTG ATTGGACGGC TACAATGAAT GTCAACTTCG ACCGTATCGA CAATCCGTCC 360 ATCACTGTCC AGCATCCCGT TCAGGTTCAG GTCACGTCAT ACAACAACAA CAGCTACAGG 420 GTTCGCTTCA ACCCTGATGG CCCTATTCGT GATGTGACTC GTGGGCCTAT CCTCAAGCAG 480 CAACTAGATT GGATTCGAAC GCAGGAGCTG TCAGAGGGAT GTGATCCCGG AATGACTTTC 540 ACATCAGAAG GTTTCTTGAC TTTTGAGACC AAGGATCTAA GCGTCATCAT CTACGGAAAT 600 TTCAAGACCA GAGTTACGAG AAAGTCTGAC GGCAAGGTCA TCATGGAAAA TGATGAAGTT 660 GGAACTGCAT CGTCCGGGAA CAAGTGCCGG GGATTGATGT TCGTTGATAG ATTATACGGT 720 AACGCTATCG CTTCCGTCAA CAAGAACTTC CGCAACGACG CGGTCAAGCA GGAGGGATTC 780 TATGGTGCAG GTGAAGTCAA CTGTAAGTAC CAGGACACCT ACATCTTAGA ACGCACTGGA 840 ATCGCCATGA CAAATTACAA CTACGATAAC TTGAACTATA ACCAGTGGGA CCTTAGACCT 900 CCGCATCATG ATGGTGCCCT CAACCCAGAC TATTATATTC CAATGTACTA CGCAGCACCT 960 TGGTTGATCG TTAATGGATG CGCCGGTACT TCGGAGCAGT ACTCGTATGG ATGGTTCATG 1020 GACAATGTCT CTCAATCTTA CATGAATACT GGAGATACTA CCTGGAATTC TGGACAAGAG 1080 GACCTGGCAT ACATGGGCGC GCAGTATGGA CCATTTGACC AACATTTTGP TTACGGTGCT 1140 GGGGGTGGGA TGGAATGTGT GGTCACAGCG TTCTCTCTTC TACAAGGCAA GGAGTTCGAG 1200 AACCAAGTTC TCAACAAACG TTCAGTAATG CCTCCGAAAT ACGTCTTTGG TTTCTTCCAG 1260 GGTGTTTTCG GGACTTCTTC CTTGTTGAGA GCGCATATGC CAGCAGGTGA GAACAACATC 1320 TCAGTCGAAG AAATTGTAGA AGGTTATCAA AACAACAATT TCCCTTTCGA GGGGCTCGCT 1380 GTGGACGTGG ATATGCAAGA CAACTTGCGG GTGTTCACCA CGAAGGGCGA ATTTTGGACC 1440 GCAAACAGGG TGGGTACTGG CGGGGATCCA AACAACCGAT CGGTTTTTGA ATGGGCACAT 1500 GACAAAGGCC TTGTTTGTCA GACAAATATA ACTTGCTTCC TGAGGAATGA TAACGAGGGG 1560 CAAGACTACG AGGTCAATCA GACGTTAAGG GAGAGGCAGT TGTACACGAA GAACGACTCC 1620 CTGACGGGTA CGGATTTTGG AATGACCGAC GACGGCCCCA GCGATGCGTA CATCGGTCAT 1680 CTGGACTATG GGGGTGGAGT AGAATGTGAT GCACTTTTCC CAGACTGGGG ACGGCCTGAC 1740 GTGGCCGAAT GGTGGGGAAA TAACTATAAG AAACTGTTCA GCATTGGTCT CGACTTCGTC 1800 TGGCAAGACA TGACTGTTCC AGCAATGATG CCGCACAAAA TTGGCGATGA CATCAATGTG 1860 AAACCGGATG GGAATTGGCC GAATGCGGAC GATCCGTCCA ATGGACAATA CAACTGGAAG 1920 ACGTACCATC CCCAAGTGCT TGTAACTGAT ATGCGTTATG AGAATCATGG TCGGGAACCG 1980 ATGGTCACTC AACGCAACAT TCATGCGTAT ACACTGTGCG AGTCTACTAG GAAGGAAGGG 2040 ATCGTGGAAA ACGCAGACAC TCTAACGAAG TTCCGCCGTA GCTACATTAT CAGTCGTGGT 2100 GGTTACATTG GTAACCAGCA TTTCGGGGGT ATGTGGGTGG GAGACAACTC TACTACATCA 2160 AACTACATCC AAATGATGAT TGCCAACAAT ATTAACATGA ATATGTCTTG CTTGCCTCTC 2220 GTCGGCTCCG ACATTGGAGG ATTCACCTCA TACGACAATG AGAATCAGCG AACGCCGTGT 2280 ACCGGGGACT TGATGGTGAG GTATGTGCAG GCGGGCTGCC TGTTGCCGTG GTTCAGGAAC 2340 CACTATGATA GGTGGATCGA GTCCAAGGAC CACGGAAAGG ACTACCAGGA GCTGTACATG 2400 TATCCGAATG AAATGGATAC GTTGAGGAAG TTCGTTGAAT TCCGTTATCG CTGGCAGGAA 2460 GTGTTGTACA CGGCCATGTA CCAGAATGCG GCTTTCGGAA AGCCGATTAT CAAGGCTGCT 2520 TCGATGTACA ATAACGACTC AAACGTTCGC AGGGCGCAGA ACGATCATTT CCTTCTTGGT 2580 GGACATGATG GATATCGCAT TCTGTGCGCG CCTGTTGTGT GGGAGAATTC GACCGAACGC 2640 GAATTGTACT TGCCCGTGCT GACCCAATGG TACAAATTCG GTCCCGACTT TGACACCAAG 2700 CCTCTGGAAG GAGCGATGAA CGGAGGGGAC CGAATTTACA ACTACCCTGT ACCGCAAAGT 2760 GAATCACCAA TCTTCGTGAG AGAAGGTGCG ATTCTCCCTA CCCGCTACAC GTTGAACGGT 2820 GAAAACAAAT CATTGAACAC GTACACGGAC GAAGATCCGT TGGTGTTTGA AGTATTCCCC 2880 CTCGGAAACA ACCGTGCCGA CGGTATGTGT TATCTTGATG ATGGCGGTGT GACCACCAAT 2940 GCTGAAGACA ATGGCAAGTT CTCTGTCGTC AAGGTGGCAG CGGAGCAGGA TGGTGGTACG 3000 GAGACGATAA CGTTTACGAA TGATTGCTAT GAGTACGTTT TCGGTGGACC GTTCTACGTT 3060 CGAGTGCGCG GCGCTCAGTC GCCGTCGAAC ATCCACGTGT CTTCTGGAGC GGGTTCTCAG 3120 GACATGAAGG TGAGCTCTGC CACTTCCAGG GCTGCGCTGT TCAATGACGG GGAGAACGGT 3180 GATTTCTGGG TTGACCAGGA GACAGATTCT CTGTGGCTGA AGTTGCCCAA CGTTGTTCTC 3240 CCGGACGCTG TGATCACAAT TACCTAA 3267 (2) INFORMATION FOR SEQ ID NO 8 (i) SEQUENCE CHARACTERISTICS (A) LENGTH 3276 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY linear (n) MOLECULE TYPE- DNA (genomic) (xi) SEQUENCE DESCRIPTION. SEQ ID NO: 8- ATGTATCCAA CCCTCACCTT CGTGGCGCCT AGTGCGCTAG GGGCCAGAAC TTTCACGTGT 60 GTGGGCATTT TTAGGTCACA CATTCTTATT CATTCGGTTG TTCCAGCGGT GCGTCTAGCT 120 GTGCGCAAAA GCAACCGCCT CAATGTATCC ATGTCCGCTT TGTTCGACAA ACCGACTGCT 180 GTTACTGGAG GGAAGGACAA CCCGGACAAT ATCAATTACA CCACTTATGA CTACGTCCCT 240 GTGTGGCGCT TCGACCCCCT CAGCAATACG AACTGGTTTG CTGCCGGATC TTCCACTCCC 300 GGCGATATTG ACGACTGGAC GGCGACAATG AATGTGAACT TCGACCGTAT CGACAATCCA 360 TCCTTCACTC TCGAGAAACC GGTTCAGGTT CAGGTCACGT CATACAAGAA CAATTGTTTC 420 AGGGTTCGCT TCAACCCTGA TGGTCCTATT CGCGATGTGG ATCGTGGGCC TATCCTCCAG 480 CAGCAACTAA ATTGGATCCG GAAGCAGGAG CAGTCGAAGG GGTTTGATCC TAAGATGGGC 540 TTCACAAAAG AAGGTTTCTT GAAATTTGAG ACCAAGGATC TGAACGTTAT CATATATGGC 600 AATTTTAAGA CTAGAGTTAC GAGGAAGAGG GATGGAAAAG GGATCATGGA GAATAATGAA 660 GTGCCGGCAG GATCGTTAGG GAACAAGTGC CGGGGATTGA TGTTTGTCGA CAGGTTGTAC 720 GGCACTGCCA TCGCTTCCGT TAATGAAAAT TACCGCAACG ATCCCGACAG GAAAGAGGGG 780 TTCTATGGTG CAGGAGAAGT AAACTGCGAG TTTTGGGACT CCGAACAAAA CAGGAACAAG 840 TACATCTTAG AACGAACTGG AATCGCCATG ACAAATTACA ATTATGACAA CTATAACTAC 900 AACCAGTCAG ATCTTATTGC TCCAGGATAT CCTTCCGACC CGAACTTCTA CATTCCCATG 960 TATTTTGCAG CACCTTGGGT AGTTGTTAAG GGATGCAGTG GCAACAGCGA 1 TGAACAGTAC 1020 TCGTACGGAT GGTTTATGGA TAATGTCTCC CAAACTTACA TGAATACTGG TGGTACTTCC 1080 TGGAACTGTG GAGAGGAGAA CTTGGCATAC ATGGGAGCAC AGTGCGGTCC ATTTGACCAA 1140 CATTTTGTGT ATGGTGATGG AGATGGTCTT GAGGATGTTG TCCAAGCGTT CTCTCTTCTG 1200 CAAGGCAAAG AGTTTGAGAA CCAAGTTCTG AACAAACGTG CCGTAATGCC TCCGAAATAT 1260 GTGTTTGGTT ACTTTCAGGG AGTCTTTGGG ATTGCTTCCT TGTTGAGAGA GCAAAGACCA 1320 GAGGGTGGTA ATAACATCTC TGTTCAAGAG ATTGTCGAAG GTTACCAAAG CAATAACTTC 1380 CCTTTAGAGG GGTTAGCCGT AGATGTGGAT ATGCAACAAG ATTTGCGCGT GTTCACCACG 1440 AAGATTGAAT TTTGGACGGC AAATAAGGTA GGCACCGGGG GAGACTCGAA TAACAAGTCG 1500 GTGTTTGAAT GGGCACATGA CAAAGGCCTT GTATGTCAGA CGAATGTTAC TTGCTTCTTG 1560 AGAAACGACA ACGGCGGGGC AGATTACGAA GTCAATCAGA CATTGAGGGA GAAGGGTTTG 1620 TACACGAAGA ATGACTCACT GACGAACACT AACTTCGGAA CTACCAACGA CGGGCCGAGC 1680 GATGCGTACA TTGGACATCT GGACTATGGT GGCGGAGGGA ATTGTGATGC ACTTTTCCCA 1740 GACTGGGGTC GACCGGGTGT GGCTGAATGG TGGGGTGATA ACTACAGCAA GCTCTTCAAA 1800 ATTGGTCTGG ATTTCGTCTG GCAAGACATG ACAGTTCCAG CTATGATGCC ACACAAAGTT 1860 GGCGACGCAG TCGATACGAG ATCACCTTAC GGCTGGCCGA ATGAGAATGA TCCTTCGAAC 1920 GGACGATACA ATTGGAAATC TTACCATCCA CAAGTTCTCG TAACTGATAT GCGATATGAG 1980 AATCATGGAA GGGAACCGAT GTTCACTCAA CGCAATATGC ATGCGTACAC ACTCTGTGAA 2040 TCTACGAGGA AGGAAGGGAT TGTTGCAAAT GCAGACACTC TAACGAAGTT CCGCCGCAGT 2100 TATATTATCA GTCGTGGAGG TTACATTGGC AACCAGCATT TTGGAGGAAT GTGGGTTGGA 2160 GACAACTCTT CCTCCCAAAG ATACCTCCAA ATGATGATCG CGAACATCGT CAACATGAAC 2220 ATGTCTTGCC TTCCACTAGT TGGGTCCGAC ATTGGAGGTT TTACTTCGTA TGATGGACGA 2280 AACGTGTGTC CCGGGGATCT AATGGTAAGA TTCGTGCAGG CGGGTTGCTT ACTACCGTGG 2340 TTCAGAAACC ACTATGGTAG GTTGGTCGAG GGCAAGCAAG AGGGAAAATA CTATCAAGAA 2400 CTGTACATGT ACAAGGACGA GATGGCTACA TTGAGAAAAT TCATTGAATT CCGTTACCGC 2460 TGGCAGGAGG TGTTGTACAC TGCTATGTAC CAGAATGCGG CTTTCGGGAA ACCGATTATC 2520 AAGGCAGCTT CCATGTACGA CAACGACAGA AACGTTCGCG GCGCACAGGA TGACCACTTC 2580 CTTCTCGGCG GACACGATGG ATATCGTATT TTGTGTGCAC CTGTTGTGTG GGAGAATACA 2640 ACCAGTCGCG ATCTGTACTT GCCTGTGCTG ACCAAATGGT ACAAATTCGG CCCTGACTAT 2700 GACACCAAGC GCCTGGATTC TGCGTTGGAT GGAGGGCAGA TGATTAAGAA CTATTCTGTG 2760 CCACAAAGCG ACTCTCCGAT ATTTGTGAGG GAAGGAGCTA TTCTCCCTAC CCGCTACACG 2820 TTGGACGGTT CGAACAAGTC AATGAACACG TACACAGACA AAGACCCGTT GGTGTTTGAG GTATTCCCTC TTGGAAACAA CCGTGCCGAC GGTATGTGTT ATCTTGATGA TGGCGGTATT 2940 ACTACAGATG CTGAGGACCA TGGCAAATTC TCTGTTATCA ATGTCGAAGC CTTACGGAAA 3000 GGTGTTACGA CGACGATCAA GTTTGCGTAT GACACTTATC AATACGTATT TGATGGTCCA 3060 TTCTACGTTC GAATCCGTAA TCTTACGACT GCATCAAAAA TTAACGTGTC TTCTGGAGCG 3120 GGTGAAGAGG ACATGACACC GACCTCTGCG AACTCGAGGG CAGCTTTGTT CAGTGATGGA 3180 GGTGTTGGAG AATACTGGGC TGACAATGAT ACGTCTTCTC TGTGGATGAA GTTGCCAAAC 3240 CTGGTTCTGC AAGACGCTGT GATTACCATT ACGTAG 3276 (2) INFORMATION FOR SEQ ID NO 9 (i) SEQUENCE CHARACTERISTICS (A) LENGTH 3201 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY linear (n) MOLECULE TYPE DNA (genomic) (xi) SEQUENCE DESCRIPTION SEQ ID ATGGCAGGAT TTTCTGATCC TCTCAACTTT TGCAAAGCAG AAGACTACTA CAGTGTTGCG 60 CTAGACTGGA AGGGCCCTCA AAAAATCATT GGAGTAGACA CTACTCCTCC AAAGAGCACC 120 AAGTTCCCCA AAAACTGGCA TGGAGTGAAC TTGAGATTCG ATGATGGGAC TTTAGGTGTG 180 GTTCAGTTCA TTAGGCCGTG CGTTTGGAGG GTTAGATACG ACCCTGGTTT CAAGACCTCT 240 GACGAGTATG GTGATGAGAA TACGAGGACA ATTGTGCAAG ATTATATGAG TACTCTGAGT 300 AATAAATTGG ATACTTATAG AGGTCTTACG TGGGAAACCA AGTGTGAGGA TTCGGGAGAT 360 TTCTTTACCT TCTCATCCAA GGTCACCGCC GTTGAAAAAT CCGAGCGGAC CCGCAACAAG 420 GTCGGCGATG GCCTCAGAAT TCACCTATGG AAAAGCCCTT TCCGCATCCA AGTAGTGCGC 480 ACCTTGACCC CTTTGAAGGA TCCTTACCCC ATTCCAAATG TAGCCGCAGC CGAAGCCCGT 540 GTGTCCGACA AGGTCGTTTG GCAAACGTCT CCCAAGACAT TCAGAAAGAA CCTGCATCCG 600 CAACACAAGA TGCTAAAGGA TACAGTTCTT GACATTGTCA AACCTGGACA TGGCGAGTAT 660 GTGGGGTGGG GAGAGATGGG AGGTATCCAG TTTATGAAGG AGCCAACATT CATGAACTAT 720 TTTAACTTCG ACAATATGCA ATACCAGCAA GTCTATGCCC AAGGTGCTCT CGATTCTCGC 780 GAGCCACTGT ACCACTCGGA TCCCTTCTAT CTTGATGTGA ACTCCAACCC GGAGCACAAG AATATCACGG CAACCTTTAT CGATAACTAC TCTCAAATTG CCATCGACTT TGGAAAGACC 900 AACTCAGGCT ACATCAAGCT GGGAACCAGG TATGGTGGTA TCGATTGTTA 1 CGGTATCAGT 960 GCGGATACGG TCCCGGAAAT TGTACGACTT TATACAGGTC TTGTTGGACG TTCAAAGTTG 1020 AAGCCCAGAT ATATTCTCGG GGCCCATCAA GCCTGTTATG GATACCAACA GGAAAGTGAC 1080 TTGTATTCTG TGGTCCAGCA GTACCGTGAC TGTAAATTTC CACTTGACGG GATTCACGTC 1140 GATGTCGATG TTCAGGACGG CTTCAGAACT TTCACCACCA ACCCACACAC TTTCCCTAAC 1200 CCCAAAGAGA TGTTTACTAA CTTGAGGAAT AATGGAATCA AGTGCTCCAC CAATATCACT 1260 CCTGTTATCA GCATTAACAA CAGAGAGGGT GGATACAGTA CCCTCCTTGA GGGAGTTGAC 1320 AAAAAATACT TTATCATGGA CGACAGATAT ACCGAGGGAA CAAGTGGGAA TGCGAAGGAT 1380 GTTCGGTACA TGTACTACGG TGGTGGTAAT AAGGTTGAGG TCGATCCTAA TGATGTTAAT 1440 GGTCGGCCAG ACTTTAAAGA CAACTATGAC TTCCCCGCGA ACTTCAACAG CAAACAATAC 1500 CCCTATCATG GTGGTGTGAG CTACGGTTAT GGGAACGGTA GTGCAGGTTT TTACCCGGAC 1560 CTCAACAGAA AGGAGGTTCG TATCTGGTGG GGAATGCAGT ACAAGTATCT CTTCGATATG 1620 GGACTGGAAT TTGTGTGGCA AGACATGACT ACCCCAGCAA TCCACACATC ATATGGAGAC 1680 ATGAAAGGGT TGCCCACCCG TCTACTCGTC ACCTCAGACT CCGTCACCAA TGCCTCTGAG 1740 AAAAAGCTCG CAATTGAAAC TTGGGCTCTC TACTCCTACA ATCTCCACAA AGCAACTTGG 1800 CATGGTCTTA GTCGTCTCGA ATCTCGTAAG AACAAACGAA ACTTCATCCT CGGGCGTGGA 1860 AGTTATGCCG GAGCCTATCG TTTTGCTGGT CTCTGGACTG GGGATAATGC AAGTAACTGG 1920 GAATTCTGGA AGATATCGGT CTCTCAAGTT CTTTCTCTGG GCCTCAATGG TGTGTGCATC 1980 GCGGGGTCTG ATACGGGTGG TTTTGAACCC TACCGTGATG CAAATGGGGT CGAGGAGAAA 2040 TACTGTAGCC CAGAGCTACT CATCAGGTGG TATACTGGTT CATTCCTCTT GCCGTGGCTC 2100 AGGAACCATT ATGTCAAAAA GGACAGGAAA TGGTTCCAGG AACCATACTC GTACCCCAAG 2160 CATCTTGAAA CCCATCCAGA ACTCGCAGAC CAAGCATGGC TCTATAAATC CGTTTTGGAG 2220 ATCTGTAGGT ACTATGTGGA GCTTAGATAC TCCCTCATCC AACTACTTTA CGACTGCATG 2280 TTTCAAAACG TAGTCGACGG TATGCCAATC ACCAGATCTA TGCTCTTGAC CGATACTGAG 2340 GATACCACCT TCTTCAACGA GAGCCAAAAG TTCCTCGACA ACCAATATAT GGCTGGTGAC 2400 GACATTCTTG TTGCACCCAT CCTCCACAGT CGCAAAGAAA TTCCAGGCGA AAACAGAGAT 2460 GTCTATCTCC CTCTTTACCA CACCTGGTAC CCCTCAAATT TGAGACCATG GGACGATCAA 2520 GGAGTCGCTT TGGGGAATCC TGTCGAAGGT GGTAGTGTCA TCAATTATAC TGCTAGGATT 2580 GTTGCACCCG AGGATTATAA TCTCTTCCAC AGCGTGGTAC CAGTCTACGT TAGAGAGGGT 2640 GCCATCATCC CGCAAATCGA AGTACGCCAA TGGACTGGCC AGGGGGGAGC CAACCGCATC 2700 AAGTTCAACA TCTACCCTGG AAAGGATAAG GAGTACTGTA CCTATCTTGA TGATGGTGTT 2760 AGCCGTGATA GTGCGCCGGA AGACCTCCCA CAGTACAAAG AGACCCACGA ACAGTCGAAG 2820 GTTGAAGGCG CGGAAATCGC AAAGCAGATT GGAAAGAAGA CGGGTTACAA CATCTCAGGA 2880 ACCGACCCAG AAGCAAAGGG TTATCACCGC AAAGTTGCTG TCACACAAAC GTCAAAAGAC 2940 AAGACGCGTA CTGTCACTAT TGAGCCAAAA CACAATGGAT ACGACCCTTC CAAAGAGGTG 3000 GGTGATTATT ATACCATCAT TCTTTGGTAC GCACCAGGTT TCGATGGCAG CATCGTCGAT 3060 GTGAGCAAGA CGACTGTGAA TGTTGAGGGT GGGGTGGAGC ACCAAGTTTA TAAGAACTCC 3120 GATTTACATA CGGTTGTTAT CGACGTGAAG GAGGTGATCG GTACCACAAA GAGCGTCAAG 3180 ATCACATGTA CTGCCGCTTA A 3201 (2) INFORMATION FOR SEQ ID NO 10 (i) SEQUENCE CHARACTERISTICS (A) LENGTH 3213 base pairs (B) TYPE nucleic acid (C) STRANDEDNESS double (D) TOPOLOGY linear (n) MOLECULE TYPE DNA (genomic) (xi) SEQUENCE DESCRIPTION SEQ ID NO 10 ATGGCAGGAT TATCCGACCC TCTCAATTTC TGCAAAGCAG AGGACTACTA CGCTGCTGCC 60 AAAGGCTGGA GTGGCCCTCA GAAGATCATT CGCTATGACC AGACCCCTCC TCAGGGTACA 120 AAAGATCCGA AAAGCTGGCA TGCGGTAAAC CTTCCTTTCG ATGACGGGAC TATGTGTGTA 180 GTGCAATTCG TCAGACCCTG TGTTTGGAGG GTTAGATATG ACCCCAGTGT CAAGACTTCT 240 GATGAGTACG GCGATGAGAA TACGAGGACT ATTGTACAAG ACTACATGAC TACTCTGGTT 300 GGAAACTTGG ACATTTTCAG AGGTCTTACG TGGGTTTCTA CGTTGGAGGA TTCGGGCGAG 360 TACTACACCT TCAAGTCCGA AGTCACTGCC GTGGACGAAA CCGAACGGAC TCGAAACAAG 420 GTCGGCGACG GCCTCAAGAT TTACCTATGG AAAAATCCCT TTCGCATCCA GGTAGTGCGT 480 CTCTTGACCC CCCTGGTGGA CCCTTTCCCC ATTCCCAACG TAGCCAATGC CACAGCCCGT 540 GTGGCCGACA AGGTTGTTTG GCAGACGTCC CCGAAGACGT TCAGGAAAAA CTTGCATCCG 600 CAGCATAAGA TGTTGAAGGA TACAGTTCTT GATATTATCA AGCCGGGGCA CGGAGAGTAT 660 GTGGGTTGGG GAGAGATGGG AGGCATCGAG TTTATGAAGG AGCCAACATT CATGAATTAT 720 TTCAACTTTG ACAATATGCA ATATCAGCAG GTCTATGCAC AAGGCGCTCT TGATAGTCGT 780 GAGCCGTTGT ATCACTCTGA TCCCTTCTAT CTCGACGTGA ACTCCAACCC AGAGCACAAG 840 AACATTACGG CAACCTTTAT CGATAACTAC TCTCAGATTG CCATCGACTT TGGGAAGACC 900 AACTCAGGCT ACATCAAGCT GGGTACCAGG TATGGCGGTA TCGATTGTTA 1 CGGTATCAGC 960 GCGGATACGG TCCCGGAGAT TGTGCGACTT TATACTGGAC TTGTTGGGCG TTCGAAGTTG 1020 AAGCCCAGGT ATATTCTCGG AGCCCACCAA GCTTGTTATG GATACCAGCA GGAAAGTGAC 1080 TTGCATGCTG TTGTTCAGCA GTACCGTGAC ACCAAGTTTC CGCTTGATGG GTTGCATGTC 1140 GATGTCGACT TTCAGGACAA TTTCAGAACG TTTACCACTA ACCCGATTAC GTTCCCTAAT 1200 CCCAAAGAAA TGTTTACCAA TCTAAGGAAC AATGGAATCA AGTGTTCCAC CAACATCACC 1260 CCTGTTATCA GTATCAGAGA TCGCCCGAAT GGGTACAGTA CCCTCAATGA GGGATATGAT 1320 AAAAAGTACT TCATCATGGA TGACAGATAT ACCGAGGGGA CAAGTGGGGA CCCGCAAAAT 1380 GTTCGATACT CTTTTTACGG CGGTGGGAAC CCGGTTGAGG TTAACCCTAA TGATGTTTGG 1440 GCTCGGCCAG ACTTTGGAGA CAATTATGAC TTCCCTACGA ACTTCAACTG CAAAGACTAC 1500 CCCTATCATG GTGGTGTGAG TTACGGATAT GGGAATGGCA CTCCAGGTTA CTACCCTGAC 1560 CTTAACAGAG AGGAGGTTCG TATCTGGTGG GGATTGCAGT ACGAGTATCT CTTCAATATG 1620 GGACTAGAGT TTGTATGGCA AGATATGACA ACCCCAGCGA TCCATTCATC ATATGGAGAC 1680 ATGAAAGGGT TGCCCACCCG TCTGCTCGTC ACCGCCGACT CAGTTACCAA TGCCTCTGAG 1740 AAAAAGCTCG CAATTGAAAG TTGGGCTCTT TACTCCTACA ACCTCCATAA AGCAACCTTC 1800 CACGGTCTTG GTCGTCTTGA GTCTCGTAAG AACAAACGTA ACTTCATCCT CGGACGTGGT 1860 AGTTACGCCG GTGCCTATCG TTTTGCTGGT CTCTGGACTG GAGATAACGC AAGTACGTGG 1920 GAATTCTGGA AGATTTCGGT CTCCCAAGTT CTTTCTCTAG GTCTCAATGG TGTGTGTATA 1980 GCGGGGTCTG ATACGGGTGG TTTTGAGCCC GCACGTACTG AGATTGGGGA GGAGAAATAT 2040 TGCAGTCCGG AGCTACTCAT CAGGTGGTAT ACTGGATCAT TCCTTTTGCC ATGGCTTAGA 2100 AACCACTACG TCAAGAAGGA CAGGAAATGG TTCCAGGAAC CATACGCGTA CCCCAAGCAT 2160 CTTGAAACCC ATCCAGAGCT CGCAGATCAA GCATGGCTTT ACAAATCTGT TCTAGAAATT 2220 TGCAGATACT GGGTAGAGCT AAGATATTCC CTCATCCAGC TCCTTTACGA CTGCATGTTC 2280 CAAAACGTGG TCGATGGTAT GCCACTTGCC AGATCTATGC TCTTGACCGA TACTGAGGAT 2340 ACGACCTTCT TCAATGAGAG CCAAAAGTTC CTCGATAACC AATATATGGC TGGTGACGAC 2400 ATCCTTGTAG CACCCATCCT CCACAGCCGT AACGAGGTTC CGGGAGAGAA CAGAGATGTC 2460 TATCTCCCTC TATTCCACAC CTGGTACCCC TCAAACTTGA GACCGTGGGA CGATCAGGGA 2520 GTCGCTTTAG GGAATCCTGT CGAAGGTGGC AGCGTTATCA ACTACACTGC CAGGATTGTT 2580 GCCCCAGAGG ATTATAATCT CTTCCACAAC GTGGTGCCGG TCTACATCAG AGAGGGTGCC 2640 ATCATTCCGC AAATTCAGGT ACGCCAGTGG ATTGGCGAAG GAGGGCCTAA TCCCATCAAG 2700 TTCAATATCT ACCCTGGAAA GGACAAGGAG TATGTGACGT ACCTTGATGA TGGTGTTAGC 2760 CGCGATAGTG CACCAGATGA CCTCCCGCAG TACCGCGAGG CCTATGAGCA AGCGAAGGTC 2820 GAAGGCAAAG ACGTCCAGAA GCAACTTGCG GTCATTCAAG GGAATAAGAC TAATGACTTC 2880 TCCGCCTCCG GGATTGATAA GGAGGCAAAG GGTTATCACC GCAAAGTTTC TATCAAACAG 2940 GAGTCAAAAG ACAAGACCCG TACTGTCACC ATTGAGCCAA AACACAACGG ATACGACCCC 3000 TCTAAGGAAG TTGGTAATTA TTATACCATC ATTCTTTGGT ACGCACCGGG CTTTGACGGC 3060 AGCATCGTCG ATGTGAGCCA GGCGACCGTG AACATCGAGG GCGGGGTGGA ATGCGAAATT 3120 TTCAAGAACA CCGGCTTGCA TACGGTTGTA GTCAACGTGA AAGAGGTGAT CGGTACCACA 3180 AAGTCCGTCA AGATCACTTG CACTACCGCT TAG 3213 SEQ. ID. NO. 11 SEQUENCE TYPE NUCLEIC ACID MOLECULE TYPE DNA (GENOMIC) ORIGINAL SOURCE ALGAL SEQUENCE LENGTH 3279 BP STRANDEDNESS DOUBLE SEQUENCE 10 20 30 40 50 60 I I I I I I 1 ATGTTTCCTA CCCTGACCTT CATAGCGCCC AGCGCGCTGG CCGCCAGCAC CTTTGTGGGC 61 GCGGATATCC GATCGGGCAT TCGCATTCAA TCCGCTCTTC CGGCCGTGCG CAACGCTGTG 121 CGCAGGAGCA AACATTACAA TGTATCCATG ACCGCATTGT CTGACAAGCA AACCGCTATC 181 AGTATTGGCC CTGACAATCC GGACGGTATC AACTACCAAA ACTACGATTA CATCCCTGTA 241 GCGGGCTTTA CGCCCCTCTC CAACACCAAC TGGTATGCTG CCGGCTCTTC CACTCCGGGC 301 GGCATCACCG ACTGGACCGC TACCATGAAT GTCAAATTCG ACCGCATTGA CAATCCGTCG 361 TACTCCAATA ACCATCCTGT TCAGATTCAG GTCACGTCGT ACAACAACAA CAGCTTCAGG 421 ATTCGCTTCA ACCCTGATGG CCCCATTCGT GACGTCTCTC GAGGACCTAT CCTGAAACAG 481 CAACTCACTT GGATTCGAAA CCAGGAGCTG GCGCAGGGAT GTAATCCGAA CATGAGCTTC 541 TCTCCTGAAG GTTTTTTGTC TTTTGAAACC AAAGACCTAA ACGTTATAAT CTACGGCAAC 601 TGCAAGATGA GAGTCACGAA GAAGGATGGC TACCTCGTCA TGGAGAATGA CGAGTGCAAC 661 TCGCAATCAG ATGGCAATAA GTGTAGAGGA TTGATGTACG TTGACCGGCT ATACGGTAAT 721 GCTATTGCTT CCGTACAAAC GAATTTTCAC AAAGACACTT CTCGGAACGA GAAATTCTAT 781 GGTGCAGGTG AAGTCAACTG TCGCTATGAG GAGCAGGGTA AGGCGCCGAC TTATGTTCTA 841 GAACGCTCTG GACTCGCCAT GACCAATTAC AATTACGACA ACTTGAACTA CAACCAACCA 901 GACGTCGTTC CTCCAGGTTA TCCCGACCAT CCCAACTACT ACATTCCAAT GTACTACGCA 961 GCACCGTGGT TGGTCGTTCA GGGATGCGCG GGGACATCGA AGCAATACTC GTACGGTTGG 1021 TTTATGGACA ATGTCTCTCA GTCGTACATG AACACTGGAG AACGGCGTG GAACTGCGGA 1081 CAGGAAAACC TGGCATACAT GGGCGCGCAA TACGGGCCAT TTGATCAGCA CTTTGTGTAT 1141 GGTGATGGAG ATGGCCTTGA AGATGTCGTC AAAGCGTTCT CCTTTCTTCA AGGAAAGGAG 1201 TTCGAAGACA AAAAACTCAA CAAGCGTTCT GTAATGCCTC CGAAGTACGT GTTTGGTTTC 1261 TTCCAGGGTG TTTTCGGTGC ACTTTCACTG TTGAAGCAGA ATCTGCCTGC CGGAGAGAAC 1321 AACATCTCAG TGCAAGAGAT TGTGGAGGGT TACCAGGATA ACGACTACCC CTTTGAAGGG 1381 CTCGCGGTAG ATGTTGATAT GCAAGATGAT CTGCGAGTGT TTACTACCAA ACCAGAATAT 1441 TGGTCGGCAA ACATGGTAGG CGAAGGCGGT GATCCTAATA ACAGATCAGT CTTTGAATGG 1501 GCACATGACA GGGGCCTTGT CTGTCAGACG AACGTAACTT GCTTCTTGAG GAACGATAAC 1561 AGTGGGAAAC CATACGAAGT GAATCAGACA TTGAGGGAGA AACAGTTGTA TACGAAGAAT 1621 GATTCCTTGA ACAACACCGA TTTTGGAACT ACCTCGGATG GGCCTGGCGA TGCGTACATT 1681 GGACATTTGG ACTATGGTGG TGGAGTGGAG TGTGATGCAA TCTTCCCAGA CTGGGGTCGA 1741 CCAGACGTGG CTCAATGGTG GGGAGAAAAC TACAAGAAGC TGTTCAGCAT TGGTCTCGAT 1801 TTCGTGTGGC AGGATATGAC GGTACCTGCG ATGATGCCGC ACCGACTCGG TGATGCTGTC 1861 AACAAAAATT CCGGTAGTTC GGCGCCGGGC TGGCCGAATG AGAACGATCC ATCCAACGGA 1921 CGATACAACT GGAAATCTTA TCATCCGCAA GTGCTCGTGA CCGACATGCG CTATGGTGCA 1981 GAGTATGGAA GGGAACCGAT GGTGTCTCAA CGCAACATTC ACGCCTACAC TCTTTGTGAA 2041 TCTACCAGAC GGGAGGGAAT TGTGGGAAAC GCAGACAGTT TGACCAAGTT CCGCCGCAGT 2101 TACATCAT-CA GTCGAGGAGG TTACATCGGT AACCAGCATT TCGGAGGGAT GTGGGTTGGG 2161 GACAACAGTG CCACAGAATC CTACCTCCAA ATGATGTTGG CGAACATTAT CAACATGAAT 2221 ATGTCGTGCC TCCCGCTAGT TGGCTCTGAT ATTGGCGGGT TCACCCAGTA CAATGATGCG 2281 GGCGACCCAA CCCCCGAGGA TTTGATGGTA AGATTCGTGC AGGCTGGCTG TCTGCTACCG 2341 TGGTTCAGAA ACCACTATGA CAGGTGGATT GAGTCCAAGA AGCACGGGAA GAAATACCAG 2401 GAGTTATACA TGTACCCGGG GCAAAAGGAT ACGTTGAAGA AGTTCGTTGA ATTCCGCTAC 2461 CGCTGGCAGG AGGTTTTGTA CACAGCCATG TACCAAAATG CTACCACTGG AGAGCCGATC 2521 ATCAAGGCGG CGCCCATGTA CAACAACGAC GTCAACGTGT ATAAATCGCA GAATGATCAT 2581 TTCCTTCTCG GTGGACATGA CGGCTATCGT ATTCTCTGCG CACCTGTTGT GCGCGAAAAT 2641 OCGACAAGTC GCGAAGTGTA CCTGCCTGTG TATAGCAAGT GGTTCAAATT CGGACCGGAC 2701 TTTGACACTA AGCCCTTGGA AAATGAGATT CAAGGAGGTC AGACGCTTTA TAATTACGCT 2761 GCACCGCTGA ACGATTCGCC GATATTTGTG AGGGAAGGGA CTATTCTTCC GACACGGTAC 2821 ACGCTGGACG GTGTGAACAA ATCTATCAAC ACGTACACAG ACAATGATCC GCTTGTATTT 2881 GAGCTGTTCC CTCTCGAAAA CAACCAGGCG CATGGCTTGT TCTATCATGA TGATGGCGGT 2941 GTCACCACCA ACGCTGAAGA CTTTGGCAAG TATTCTGTGA TCAGTGTGAA GGCCGCGCAG 3001 GAAGGTTCTC AAATGAGTGT CAAGTTTGAC AATGAAGTTT ATGAACACCA ATGGGGAGCA 3061 TCGTTCTATG TTCGTGTTCG TAATATGGGT GCTCCGTCTA ACATCAACGT ATCTTCTCAG 3121 ATTGGTCAAC AGGACATGCA ACAGAGCTCC GTGAGTTCCA GGGCGCAAAT GTTCACTAGT 3181 GCTAACGATG GCGAGTACTG GGTTGACCAG AGCACGAACT CGTTGTGGCT CAAGTTGCCT 3241 GGTGCAGTTA TCCAAGACGC TGCGATCACT GTTCGTTGA SEQ. ID. NO. 12 SEQUENCE TYPE: NUCLEIC ACID MOLECULE TYPE: DNA (GENOMIC) ORIGINAL SOURCE: ALGAL SEQUENCE LENGTH: 1712 BP STRANDEDNESS: DOUBLE SEQUENCE: 10 20 30 40 50 60 I I 1 I I I 1 ATGACAAACT ATAATTATGA CAATTTGAAC TACAATCAAC CGGACCTCAT CCCACCTGGC 61 CATGATTCAG ATCCTGACTA CTATATTCCG ATGTACTTTG CGGCACCATG GGTGATCGCA 121 CATGGATATC GTGGCACCAG CGACCAGTAC TCTTATGGAT GGTTTTTGGA CAATGTATCC 181 CAGTCCTACA CAAACACTGG CGATGATGCA TGGGCTGGTC AGAAGGATTT GGCGTACATG 241 GGGGCACAAT GTGGGCCTTT CGATCAACAT TTTGTGTATG AGGCTGGAGA TGGACTTGAA 301 GACGTTGTGA CCGCATTCTC TTATTTGCAA GGCAAGGAAT ATGAGAACCA GGGACTGAAT 361 ATACGTTCTG CAATGCCTCC GAAGTACGTT TTCGGATTTT TCCAAGGCGT ATTCGGAGCC 421 ACATCGCTGC TAAGGGACAA CTTACCTGCC GGCGAGAACA ACGTCTCTTT GGAAGAAATT 481 GTTGAAGGAT ATCAAAATCA GAACGTGCCA TTTGAAGGTC TTGCTGTGGA TGTTGATATG 541 CAAGATGACT TGAGAGTGTT CACTACGAGA CCAGCGTTTT GGACGGCAAA CAAGGTGGGG 601 GAAGGCGGTG ATCCAAACAA CAAGTCAGTG TTTGAGTGGG CACATGACAG GGGCCTTGTC 661 TGCCAGACGA ATGTAACTTG CTTCTTGAAG AACGAGAAAA ATCCTTACGA AGTGAATCAG 721 TCATTGAGGG AGAAGCAGTT GTATACGAAG AGTGATTCCT TGGACAACAT TGATTTTGGA 781 ACTACTCCAG ATGGGCCTAG CGATGCGTAC ATTGGACACT TAGACTACGG TGGTGGTGTG 841 GAGTGTGATG CACTATTCCC AGACTGGGGT CGACCAGACG TGGCTCAATG GTGGGGCGAT 901 AACTACAAGA AACTATTCAG CATTGGTCTC GATTTCGTCT GGCAAGATAT GACGGTACCT 961 GCGATGATGC CGCACCGACT CGGTGACCCT GTCGGCACAA ATTCCGGTGA GACGGCGCCG 1021 GGCTGGCCGA ATGATAAGGA TCCATCCAAC GGACGATACA AWGGAAGTC TTACCATCCG 1081 CAAGTGCTCG TGACTGACAT GAGGTATGAC GATTACGGAA GAGATCCCAT TGTTACGCAA 1141 CGCAATCTCC ATGCCTACAC TCTTTGTGAG TCTACTAGGA GGGAAGGCAT TGTTGGAAAC 1201 GCAGATAGTC TGACGAAGTT CCGCCGCAGC TATATTATCA GTCGTGGAGG CTACATCGGT 1261 AATCAGCACT TTGGTGGGAT GTGGGTAGGA GACAACTCTT CTACGGAAGA CTACCTCGCA 1321 ATGATGGTTA TCAACGTTAT CAACATGAAC ATGTCCGGTG TCCCGCTCGT TGGTTCCGAT 1381 ATTGGAGGTT TCACGGAGCA TGACAAGAGA AACCCTTGCA CACCGGACTT GATGATGAGA 1441 TTTGTGCAGG CTGGATGCTT GCTACCGTGG TTCAGGAACC ACTACGATAG GTGGATCGAG 1501 AGCAAGAAAC ACGGAAAGAA CTACCAAGAG TTGTACATGT ACCGCGACCA CTTGGACGCC 1561 TTGAGAAGTT TTGTGGAACT CCGCTATCGC TGGCAGGAAG TGTTATACAC AGCCATGTAT 1621 CAGAATGCTT TGAACGGGAA GCCGATCATC AAAACGGTCT CCATGTACAA CAACGATATG 1681 AACGTCAAAG ATGCTCAGAA TGACCACTTC CT

Claims: CLAIMS 1. A process of preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; and wherein the anti-oxidant is prepared from a glucan by use of recombinant DNA techniques. 2. A process according to claim 1, wherein the glucan comprises α-1,4 links. 3. A process according to claim 1 or claim 2 wherein the glucan is starch. 4. A process according to any one of the preceding claims wherein the glucan is a substrate for a recombinant enzyme such that contact of the glucan with the recombinant enzyme yields the anti-oxidant. 5. A process according to any one of claims 1 to 4, wherein the enzyme is a glucan lyase. 6. A process according to claim 5, wherein the enzyme is an α-l,4-glucan lyase. 7. A process according to claim 6, wherein the enzyme comprises any one of the sequences shown as SEQ ID Nos 1-6, or a variant, homologue or fragment thereof. 8. A process according to claim 7, wherein the enzyme is any one of the sequences shown as SEQ ID Nos 1-6. 9. A process according to any one of claims 5 to 8, wherein the enzyme is encoded by a nucleotide sequence comprising any one of the sequences shown as SEQ ID Nos 7-12, or a variant, homologue or fragment thereof. 10. A process according to claim 9, wherein the enzyme is encoded by a nucleotide sequence having any one of the sequences shown as SEQ ID Nos 7-12. 11. A process according to any One of the preceding claims, wherein the antioxidant is anhydrofructose. 12. A process according to claim 11, wherein the anti-oxidant is 1 ,5-D- anhydrofructose. 13. A process according to any one of the preceding claims, wherein the medium is, or is used in the preparation of, a foodstuff. 14. A process according to claim 13, wherein the foodstuff is a beverage. 15. A process according to claim 14, wherein the beverage is an alcoholic beverage. 16. A process according to claim 14, wherein the beverage is a wine. 17. A process according to any one of the preceding claims, wherein the antioxidant is prepared in situ in the component and is then released into the medium. 18. A process according to any one of the preceding claims, wherein the component is a plant or a part thereof. 19. A process according to claim 18, wherein the component is all or part of a cereal or a fruit. 20. A process according to claim 20, wherein the component is all or part of a grape. 21. A process of preparing a medium that comprises an anti-oxidant and at least one other component, the process comprising preparing in situ in the medium the anti-oxidant; and wherein the anti-oxidant is prepared by use of a recombinant glucan lyase. 22. A process according to claim 21 wherein the glucan lyase is that as defined in any one of claims 6 to 10. 23. A medium prepared by the process according to any one of the preceding claims. 24. Use of anhydrofructose as an anti-oxidant for a medium comprising at least one other component, wherein the anhydrofructose is prepared in situ in the medium. 25. Use of anhydrofructose as a means for imparting or improving stress tolerance in a plant, wherein the anhydrofructose is prepared in situ in the plant. 26. Use of anhydrofructose as a means for imparting or improving the transformation of a grape, wherein the anhydrofructose is prepared in situ in the grape. 27. Use of glucan lyase as a means for imparting or improving stress tolerance in a plant, wherein the glucan lyase is prepared in situ in the plant. 28. Use of glucan lyase as a means for imparting or improving the transformation of a grape, wherein the glucan lyase is prepared in situ in the grape. 29. Use of a nucleotide sequence coding for a glucan lyase as a means for imparting or improving stress tolerance in a plant, wherein the nucleotide sequence is expressed in situ in the plant. 30. Use of a nucleotide sequence coding for a glucan lyase as a means for imparting or improving the transformation of a grape, wherein the nucleotide sequence is expressed in situ in the grape. 31. A process or medium substantially as described herein.

Inventors: BUCHTER-LARSEN AKSEL, MARCUSSEN IAN, BUCHTER-LARSEN, AKSEL, MARCUSSEN, IAN
Applicants: BUCHTER LARSEN AKSEL, DANISCO, MARCUSSEN IAN, BUCHTER-LARSEN, AKSEL, DANISCO A/S, MARCUSSEN, IAN
Application year: 1998
Main classification: C12N9
IPC codes: A01H1, C12N9, C12N15, C12P19